A		O
further		O
major		O
contribution		O
to		O
improving		O
K		O
(		O
i		O
)		O
values		O
and		O
inhibition		O
strength		O
was		O
the		O
hydrophobic		O
natures		O
and		O
structures		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
substituents		B-MODIFIER
.		O
Compared		O
with		O
their		O
non		O
-		O
fluorinated		O
parent		O
compounds		O
,		O
the		O
2'		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
analogues		B-MODIFIER
were		O
all		O
approximately		O
2		O
-		O
fold		O
more		O
potent		O
as		O
TS		O
inhibitors		O
.		O
A		O
new		O
series		O
of		O
thyrotropin		O
-		O
releasing		O
hormone		O
(		O
TRH		O
)		O
analogues		O
,		O
obtained		O
by		O
further		O
modifications		O
of		O
our		O
most		O
potent		O
central		O
nervous		O
system		O
(		O
CNS		O
)		O
stimulating		O
neutral		O
tripeptides		O
at		O
both		O
termini		O
,		O
were		O
synthesized		O
by		O
the		O
pentafluorophenyl		O
ester		O
method		O
and		O
tested		O
for		O
CNS		O
and		O
thyrotropin		O
(		O
TSH		O
)		O
releasing		O
activity		O
.		O
When		O
the		O
4'		O
-		O
F		O
groups		O
of		O
compounds		O
5		O
(		O
K		O
(		O
i		O
)		O
=		O
2.94		O
nM		O
)		O
and		O
8		O
(		O
K		O
(		O
i		O
)		O
=		O
6.87		O
nM		O
)		O
were		O
replaced		O
with		O
4'		O
-		O
Cl		O
in		O
the		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboalkoxy		I-IUPAC
series		B-MODIFIER
,		O
DAT		O
binding		O
affinities		O
were		O
slightly		O
reduced		O
(		O
K		O
(		O
i		O
)		O
=		O
12.6		O
and		O
14.6		O
nM		O
for		O
6		O
and		O
7		O
,		O
respectively		O
)		O
,		O
yet		O
inhibition		O
of		O
dopamine		O
uptake		O
potency		O
remained		O
comparably		O
high		O
(		O
IC		O
(		O
50		O
)		O
range		O
=		O
1.5-2.5		O
nM		O
)		O
.		O
(		O
S		O
)		O
-		O
11b		O
was		O
evaluated		O
as		O
an		O
enzyme		O
-		O
activated		O
irreversible		O
inhibitor		O
of		O
murine		O
liver		O
AADC		O
and		O
determined		O
to		O
have		O
a		O
KI		O
of		O
24.3		O
+		O
/		O
-		O
3.01		O
microM		O
and		O
a		O
k2		O
of		O
2.26		O
+		O
/		O
-		O
0.44		O
min		O
-		O
1		O
.		O
In		O
order		O
to		O
study		O
the		O
structure		O
-		O
activity		O
relationships		O
of		O
L		B-IUPAC
-		I-IUPAC
oxathiolanyl		I-IUPAC
nucleosides		B-MODIFIER
as		O
potential		O
anti		O
-		O
HIV		O
agents		O
,		O
a		O
series		O
of		O
enantiomerically		O
pure		O
L		B-IUPAC
-		I-IUPAC
oxathiolanyl		I-IUPAC
pyrimidine		I-IUPAC
and		O
purine		O
nucleosides		O
were		O
synthesized		O
and		O
evaluated		O
for		O
anti		O
-		O
HIV		O
-		O
1		O
activity		O
in		O
human		O
peripheral		O
blood		O
mononuclear		O
(		O
PBM		O
)		O
cells		O
.		O
Minimum		O
-		O
energy		O
conformations		O
of		O
pirenzepine		O
and		O
II		O
were		O
calculated		O
by		O
using		O
the		O
program		O
MacroModel		O
(		O
version		O
2.0		O
)		O
.		O
Isolated		O
[		O
D		O
-		O
Trp		O
(		O
Boc		O
)		O
4		O
,		O
Lys		O
(		O
Boc		O
)		O
5		O
,		O
Thr		O
(		O
tBu		O
)		O
6		O
]		O
octreotide		O
had		O
the		O
correct		O
molecular		O
mass		O
(		O
[		O
M+		O
H		O
]		O
+		O
=		O
1275		O
Da		O
)		O
and		O
sequence		O
and		O
was		O
obtained		O
in		O
14%		O
yield		O
at		O
&		O
gt		O
;		O
98%		O
purity		O
.		O
Selected		O
compounds		O
were		O
additionally		O
investigated		O
in		O
binding		O
assays		O
at		O
recombinant		O
A		O
(		O
3		O
)		O
ARs		O
.		O
Compound		O
10		O
provided		O
approximately		O
50%		O
protection		O
against		O
HIV		O
at		O
10		O
(		O
-		O
4		O
)		O
M		O
concentrations		O
.		O
Several		O
compounds		O
protected		O
mice		O
from		O
lethal		O
intraperitoneal		O
(		O
ip		O
)		O
infections		O
with		O
S		O
.		O
[		O
18F		O
]		O
FCWAY		O
(		O
[		O
18F		O
]		O
4d		O
)		O
gave		O
half		O
-		O
lives		O
and		O
intercepts		O
comparable		O
to		O
[		O
carbonyl		O
-		O
11C		O
]		O
4a		O
in		O
the		O
brain		O
,		O
but		O
the		O
blood		O
clearance		O
was		O
faster		O
.		O
In		O
addition		O
to		O
being		O
excreted		O
in		O
urine		O
unchanged		O
,		O
tolazamide		O
was		O
metabolized		O
to		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hexahydroazepin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
(		I-IUPAC
carboxyphenyl		I-IUPAC
)		I-IUPAC
sulfonylurea		I-IUPAC
(		O
2		O
)		O
,		O
p		B-IUPAC
-		I-IUPAC
toluenesulfonamide		I-IUPAC
(		O
3		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hexahydroazepin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethylphenyl		I-IUPAC
)		I-IUPAC
sulfonylurea		I-IUPAC
(		O
4		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyhexahydroazepin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
tolylsulfonylurea		I-IUPAC
(		O
5		O
)		O
and		O
a		O
labile		O
,		O
unidentified		O
metabolite		O
6		O
by		O
man		O
.		O
Methyl		O
5		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxyribofuranose		I-IUPAC
was		O
oxidized		O
and		O
the		O
mixture		O
of		O
the		O
3'		B-IUPAC
-		I-IUPAC
keto		I-IUPAC
derivatives		B-MODIFIER
was		O
separated		O
into		O
the		O
alpha		O
-		O
and		O
beta		O
-		O
anomers		O
.		O
B		O
.		O
The		O
Pu		O
complexes		O
of		O
the		O
CAM		O
-		O
HOPO		O
ligands		O
are		O
to		O
some		O
degree		O
unstable		O
at		O
pH		O
&		O
lt		O
;		O
7.4		O
,		O
as		O
judged		O
by		O
Pu		O
residues		O
in		O
kidneys		O
in		O
excess		O
of		O
24		O
-		O
h		O
Pu		O
-		O
injected		O
controls		O
.		O
By		O
contrast		O
,		O
alpha		O
-		O
chymotrypsin		O
inactivated		O
with		O
N		B-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
Phe		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
epoxypropyl		I-IUPAC
ester		I-IUPAC
then		O
subjected		O
to		O
amino		O
acid		O
analysis		O
showed		O
no		O
change		O
in		O
the		O
content		O
of		O
any		O
amino		O
acid		O
that		O
would		O
serve		O
as		O
a		O
potential		O
nucleophile		O
to		O
the		O
inhibitor		O
.		O
The		O
enantiomers		O
of		O
9		O
were		O
prepared		O
analogously		O
from		O
the		O
secondary		O
amine		O
27		O
.		O
The		O
GAELs		O
differ		O
from		O
1		O
in		O
having		O
the		O
sn		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphocholine		I-IUPAC
residue		O
replaced		O
by		O
one		O
of		O
the		O
following		O
monosaccharide		O
residues		O
:		O
beta		B-PARTIUPAC
-		I-PARTIUPAC
and		O
alpha		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabino		I-IUPAC
-		I-IUPAC
hexopyranosyl		I-IUPAC
,		O
alpha		B-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
mannopyranosyl		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
glucopyranosyl		I-IUPAC
,		O
and		O
2		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
mannopyranosyl		I-IUPAC
.		O
Selective		O
cleavage		O
of		O
the		O
Cbz		O
group		O
by		O
H2		O
/		O
Pd		O
gave		O
the		O
key		O
intermediate		O
tert		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
diaminopropionate		I-IUPAC
(		O
5		O
)		O
,		O
which		O
was		O
acylated		O
,		O
via		O
the		O
N		B-IUPAC
-		I-IUPAC
hydroxysuccinimide		I-IUPAC
esters		I-IUPAC
,		O
with		O
bromoacetic		B-IUPAC
acid		I-IUPAC
,		O
dichloroacetic		O
acid		O
,		O
and		O
fumaric		B-IUPAC
acid		I-IUPAC
monoethyl		I-IUPAC
ester		I-IUPAC
to		O
give		O
tert		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
propionate		I-IUPAC
(		O
6a		O
)		O
,		O
tert		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dichloroacetamido		I-IUPAC
)		I-IUPAC
propionate		I-IUPAC
(		O
6b		O
)		O
,		O
and		O
tert		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxycarbonyl		I-IUPAC
)		I-IUPAC
acrylamido		I-IUPAC
]		I-IUPAC
-		I-IUPAC
propionate		I-IUPAC
(		O
6c		O
)		O
,		O
respectively		O
.		O
Conformational		O
factors		O
appear		O
to		O
be		O
responsible		O
for		O
the		O
inability		O
of		O
the		O
trans		O
-		O
C1		O
-		O
methyl		O
-		O
substituted		O
derivative		O
of		O
1		O
to		O
activate		O
5		O
-		O
HT		O
receptors		O
.		O
The		O
analogues		O
I		O
-		O
V		O
caused		O
an		O
initial		O
rise		O
in		O
blood		O
pressure		O
(		O
30		O
min		O
of		O
infusion		O
,		O
250		O
ng		O
/		O
kg		O
/		O
min		O
in		O
vagotomized		O
ganglion		O
-		O
blocked		O
rats		O
)		O
of		O
8.05		O
,		O
11.7		O
,		O
3.50		O
,		O
4.5		O
,		O
and		O
11.16		O
mmHg		O
.		O
Xanthine		O
derivatives		O
with		O
several		O
functional		O
groups		O
at		O
the		O
1		O
-		O
or		O
7		O
-		O
position		O
were		O
synthesized		O
,		O
and		O
their		O
pharmacological		O
activities		O
in		O
guinea		O
pigs		O
were		O
studied		O
.		O
MD		O
simulations		O
revealed		O
that		O
several		O
mutations		O
,		O
including		O
Pro11		O
-		O
-		O
&		O
gt		O
;		O
Gly		O
,		O
Leu21		O
-		O
-		O
&		O
gt		O
;		O
Gly		O
,		O
Leu24		O
-		O
-		O
&		O
gt		O
;		O
Gly		O
,		O
and		O
Gln27		O
-		O
-		O
&		O
gt		O
;		O
Gly		O
,		O
cause		O
a		O
rather		O
large		O
conformational		O
alteration		O
to		O
the		O
PKC		O
binding		O
site		O
and		O
,		O
in		O
some		O
cases		O
,		O
to		O
the		O
overall		O
structure		O
of		O
the		O
protein		O
.		O
Compounds		O
3		O
and		O
4		O
were		O
likewise		O
found		O
to		O
be		O
inactive		O
and		O
only		O
marginal		O
activity		O
was		O
exhibited		O
by		O
5		O
.		O
A		O
is		O
our		O
previously		O
reported		O
potent		O
and		O
selective		O
antagonist		O
of		O
the		O
vasopressor		O
(		O
V1		O
receptor		O
)		O
responses		O
to		O
arginine		O
-		O
vasopressin		O
(		O
AVP		O
)		O
/		O
weak		O
oxytocin		O
antagonist		O
,		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
,		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
pentamethylenepropionic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyltyrosine		I-IUPAC
]		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
(		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
]		O
AVP		O
.		O
A		O
minor		O
product		O
formed		O
in		O
both		O
cases		O
was		O
a		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
derivative		B-MODIFIER
in		O
which		O
the		O
nucleoside		O
5'		B-IUPAC
-		I-IUPAC
hydroxyl		I-IUPAC
group		B-MODIFIER
had		O
been		O
replaced		O
by		O
chlorine		O
(		O
6		O
and		O
8		O
)		O
.		O
5		B-IUPAC
-		I-IUPAC
Methyl		I-IUPAC
and		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
substitution		B-MODIFIER
was		O
also		O
favorable		O
,		O
with		O
the		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogue		B-MODIFIER
being		O
2		O
.		O
Among		O
the		O
latter		O
compounds		O
,		O
the		O
3		B-IUPAC
-		I-IUPAC
alkylamino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
pentyl		I-IUPAC
derivative		B-MODIFIER
(		O
11a		O
)		O
showed		O
a		O
clear		O
selectivity		O
for		O
the		O
vascular		O
smooth		O
muscle		O
tissue		O
.		O
The		O
T		O
.		O
Variations		O
of		O
the		O
1		O
-		O
substituent		O
at		O
the		O
indole		O
and		O
of		O
the		O
chain		O
length		O
of		O
the		O
alkylene		O
spacer		O
group		O
were		O
studied		O
.		O
Cyclic		O
depsipeptide		O
cyclo		O
-		O
[		O
D		O
-		O
Hmp		O
(		O
1		O
)		O
-		O
L		O
-		O
MeVal		O
(		O
2		O
)		O
-		O
L		O
-		O
Phe		O
(		O
3		O
)		O
-		O
L		O
-		O
MePhe		O
(		O
4		O
)		O
-		O
L		O
-		O
Pro		O
(		O
5		O
)		O
-		O
L		O
-		O
aIle+		O
+		O
+		O
(		O
6		O
)		O
-		O
L		O
-		O
MeVal		O
(		O
7		O
)		O
-		O
L		O
-		O
Leu		O
(		O
8		O
)		O
-		O
L		O
-		O
betaHOMeVal		O
(		O
9		O
)		O
]		O
,		O
the		O
antifungal		O
antibiotic		O
aureobasidin		O
A		O
(		O
AbA		O
)		O
,		O
was		O
reported		O
to		O
interfere		O
with		O
ATP		O
-		O
binding		O
cassette		O
(		O
ABC		O
)		O
transporters		O
in		O
yeast		O
and		O
mammalian		O
cells		O
,		O
particularly		O
the		O
MDR1		O
P		O
-		O
glycoprotein		O
(		O
Pgp		O
)		O
,		O
a		O
transmembrane		O
phospholipid		O
flippase		O
or		O
"		O
hydrophobic		O
vacuum		O
cleaner		O
"		O
that		O
mediates		O
multidrug		O
resistance		O
(		O
MDR		O
)		O
of		O
cancer		O
cells		O
.		O
Alkylation		O
of		O
adenine		O
(		O
18		O
)		O
with		O
24		O
+		O
25		O
gave		O
(		O
E		O
)		O
-		O
and		O
(		O
Z		O
)		O
-		O
bromo		O
derivatives		O
21		O
+		O
22		O
.		O
The		O
ethyl		O
esters		O
were		O
further		O
reacted		O
with		O
3		B-IUPAC
-		I-IUPAC
picolylamine		I-IUPAC
to		O
produce		O
corresponding		O
amides		O
.		O
Further		O
modifications		O
of		O
the		O
intermediate		O
led		O
to		O
the		O
syntheses		O
of		O
(		B-IUPAC
9R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
deoxo		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
12,21		I-IUPAC
-		I-IUPAC
epoxyerythromycin		I-IUPAC
B		I-IUPAC
,		O
(		B-IUPAC
9R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
deoxo		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
21		I-IUPAC
-		I-IUPAC
hydroxyerythromycin		I-IUPAC
A		I-IUPAC
,		O
and		O
(		B-IUPAC
9R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
deoxo		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
21		I-IUPAC
-		I-IUPAC
hydroxyerythromycin		I-IUPAC
B		I-IUPAC
.		O
The		O
N		B-MODIFIER
-		I-MODIFIER
6		I-MODIFIER
glycosylated		I-MODIFIER
imidazo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
isothiazoles		I-IUPAC
were		O
completely		O
inactive		O
up		O
to		O
the		O
highest		O
concentration		O
tested		O
.		O
Further		O
evaluation		O
of		O
the		O
mechanism		O
of		O
action		O
of		O
3		O
implicated		O
DHFR		O
as		O
its		O
primary		O
intracellular		O
target		O
.		O
Selected		O
derivatives		O
,		O
including		O
reversine		O
(		O
K		O
(		O
B		O
)		O
value		O
of		O
466		O
nM		O
via		O
Schild		O
analysis		O
)		O
,		O
competitively		O
antagonized		O
the		O
functional		O
effects		O
of		O
a		O
selective		O
A		O
(		O
3		O
)		O
AR		O
agonist		O
,		O
i.e.		O
,		O
inhibition		O
of		O
forskolin		O
-		O
stimulated		O
cAMP		O
production		O
in		O
stably		O
transfected		O
Chinese		O
hamster		O
ovary		O
(		O
CHO		O
)		O
cells		O
.		O
Nucleosides		O
5a		O
,		O
b		O
,		O
d		O
-		O
h		O
were		O
selectively		O
converted		O
to		O
the		O
corresponding		O
5'		O
-		O
monophosphates		O
6a		O
,		O
b		O
,		O
d		O
-		O
h		O
with		O
the		O
aid		O
of		O
the		O
wheat		O
shoot		O
phosphotransferase		O
system		O
.		O
Deprotection		O
with		O
hydrazine		O
or		O
by		O
alkaline		O
hydrolysis		O
gave		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
guanine		I-IUPAC
(		O
9		O
)		O
,		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
(		O
10		O
)		O
,		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoethoxy		I-IUPAC
]		I-IUPAC
ethoxymethyl		I-IUPAC
]		I-IUPAC
guanine		I-IUPAC
(		O
11		O
)		O
,		O
and		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
ethoxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
guanine		I-IUPAC
(		O
12		O
)		O
.		O
None		O
of		O
the		O
high		O
affinity		O
structures		O
described		O
here		O
showed		O
receptor		O
antagonism		O
.		O
The		O
substituted		O
estradiols		O
were		O
evaluated		O
for		O
estrogen		O
receptor		O
binding		O
activity		O
in		O
MCF		O
-		O
7		O
human		O
mammary		O
carcinoma		O
cells		O
,		O
and		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
estradiol		I-IUPAC
1		O
exhibited		O
the		O
highest		O
affinity		O
with		O
an		O
apparent		O
EC50		O
value		O
of		O
364		O
nM		O
.		O
Targets		O
14c		O
(		O
Z		O
-		O
isomer		O
)		O
and		O
15c		O
(		O
E		O
-		O
isomer		O
)		O
were		O
derived		O
,		O
in		O
turn		O
,		O
from		O
4,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
.		O
Particularly		O
,		O
the		O
bronchodilatory		O
effect		O
of		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
ethoxyethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
propylxanthine		I-IUPAC
was		O
much		O
stronger		O
and		O
more		O
continuous		O
than		O
those		O
of		O
theophylline		O
and		O
pentoxifylline		O
.		O
Although		O
their		O
in		O
vitro		O
antibacterial		O
activities		O
are		O
less		O
than		O
the		O
6,8		B-IUPAC
-		I-IUPAC
difluoro		I-IUPAC
analogues		B-MODIFIER
,		O
the		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
quinolones		I-IUPAC
are		O
generally		O
equivalent		O
to		O
their		O
8H		O
analogues		O
.		O
These		O
compounds		O
were		O
prepared		O
by		O
modification		O
of		O
the		O
Corey		O
prostaglandin		O
synthesis		O
utilizing		O
as		O
a		O
key		O
step		O
condensation		O
of		O
known		O
hemiacetals		O
with		O
the		O
ylide		O
derived		O
from		O
the		O
requisite		O
substituted		O
phosphonium		O
salts		O
.		O
The		O
biological		O
properties		O
conferred		O
upon		O
norepinephrine		O
by		O
the		O
fluorine		O
substituents		O
in		O
peripheral		O
and		O
central		O
adrenergically		O
responsive		O
systems		O
clearly		O
demonstrate		O
that		O
2		B-IUPAC
-		I-IUPAC
fluoronorepinephrine		I-IUPAC
is		O
a		O
nearly		O
a		O
pure		O
beta		O
-		O
adrenergic		O
agonist		O
,		O
while		O
6		B-IUPAC
-		I-IUPAC
fluoronorepinephrine		I-IUPAC
is		O
an		O
alpha		O
-		O
adrenergic		O
agonist		O
.		O
Compounds		O
3		O
and		O
23		O
have		O
similar		O
affinities		O
to		O
5		O
-		O
HT1A		O
receptors		O
,		O
whereas		O
the		O
propyl		B-IUPAC
substituent		B-MODIFIER
of		O
2		O
not		O
only		O
enhances		O
the		O
selectivity		O
for		O
D2A		O
receptors		O
but		O
also		O
increases		O
the		O
D2A		O
affinity		O
.		O
Analogues		O
1		O
,		O
2		O
,		O
3		O
,		O
and		O
5		O
have		O
also		O
been		O
shown		O
to		O
antagonize		O
the		O
in		O
vivo		O
oxytocic		O
responses		O
to		O
oxytocin		O
.		O
alpha		O
-		O
Fluoromethyl		O
amino		O
acids		O
are		O
enzyme		O
-		O
activated		O
irreversible		O
inhibitors		O
of		O
amino		O
acid		O
decarboxylases		O
.		O
Our		O
investigation		O
of		O
the		O
permeability		O
-		O
enhancing		O
properties		O
of		O
the		O
AEL		O
molecules		O
imply		O
that		O
by		O
encapsulating		O
conventional		O
chemotherapeutic		O
drugs		O
,		O
such		O
as		O
doxorubicin		O
,		O
in		O
liposomes		O
consisting		O
of		O
proAELs		O
,		O
an		O
increased		O
effect		O
of		O
the		O
encapsulated		O
drug		O
might		O
be		O
achievable		O
due		O
to		O
an		O
enhanced		O
transmembrane		O
drug		O
diffusion		O
.		O
in		O
[		B-IUPAC
(		I-IUPAC
35		I-IUPAC
)		I-IUPAC
S		I-IUPAC
]		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butylbicyclophosphorothionate		I-IUPAC
binding		O
experiments		O
,		O
(		O
2		O
)		O
.		O
4		B-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
1		O
)		O
displayed		O
good		O
activity		O
against		O
intraperitoneally		O
implanted		O
P388		O
leukemia		O
in		O
mice		O
,		O
but		O
it		O
was		O
devoid		O
of		O
activity		O
against		O
M5076		O
sarcoma		O
,		O
amelanotic		O
(		O
LOX		O
)		O
melanoma		O
xenograft		O
,		O
and		O
subrenal		O
capsule		O
human		O
mammary		O
carcinoma		O
MX		O
-		O
1		O
xenograft		O
in		O
mice		O
.		O
We		O
prepared		O
six		O
pairs		O
of		O
alpha		B-IUPAC
-		I-IUPAC
heteroaromatic		I-IUPAC
aldoximes		I-IUPAC
,		O
RC		O
(		O
=		O
NOH		O
)		O
H		O
,		O
and		O
thiohydroximates		O
,		O
RC		O
(		O
=		O
NOH		O
)		O
S		O
-		O
(		O
CH2		O
)		O
2N		O
(		O
C2H5		O
)		O
2		O
,		O
where		O
R		O
represents		O
various		O
oxadiazole		O
and		O
thiadiazole		O
rings		O
.		O
N		O
-		O
Methylation		O
in		O
the		O
beta		B-IUPAC
-		I-IUPAC
ionylideneacetamidobenzoate		I-IUPAC
series		B-MODIFIER
(		O
10c		O
)		O
also		O
results		O
in		O
the		O
formation		O
of		O
a		O
cis		O
-		O
amide		O
bond		O
and		O
loss		O
of		O
activity		O
.		O
The		O
ring		O
size		O
,		O
bridgehead		O
amino		O
acid		O
chirality		O
,		O
and		O
side		O
-		O
chain		O
amide		O
bond		O
location		O
were		O
varied		O
in		O
this		O
partial		O
series		O
in		O
an		O
attempt		O
to		O
maximize		O
potency		O
.		O
Here		O
we		O
describe		O
the		O
synthesis		O
and		O
structure		O
-		O
activity		O
relationship		O
(		O
SAR		O
)		O
studies		O
of		O
two		O
new		O
series		O
of		O
LTB4		O
receptor		O
antagonists		O
in		O
which		O
the		O
phenyl		O
ring		O
of		O
this		O
receptor		O
binding		O
domain		O
is		O
replaced		O
with		O
indole		O
and		O
naphthalene		O
,		O
respectively		O
.		O
Two		O
9,10		B-IUPAC
-		I-IUPAC
dihydrophenanthrenes		I-IUPAC
substituted		O
with		O
quaternary		O
ammonium		O
salts		O
,		O
2d		O
and		O
3d		O
,		O
each		O
containing		O
a		O
reactive		O
benzylic		B-MODIFIER
dimethyl		B-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
ammonio		I-IUPAC
group		B-MODIFIER
,		O
were		O
found		O
to		O
be		O
10-20		O
times		O
more		O
potent		O
than		O
juncusol		O
(		O
1a		O
)		O
.		O
The		O
alkenylestradiols		O
were		O
obtained		O
via		O
a		O
Stille		O
cross		O
-		O
coupling		O
between		O
a		O
MOM		O
-		O
protected		O
4		B-IUPAC
-		I-IUPAC
bromoestradiol		I-IUPAC
and		O
an		O
alkenylstannane		O
.		O
In		O
a		O
previous		O
study		O
,		O
we		O
described		O
affinity		O
labeling		O
of		O
the		O
lamb		O
uterine		O
estrogen		O
receptor		O
by		O
17		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
bromoacetoxy		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
/		I-IUPAC
alkynyl		I-IUPAC
]		I-IUPAC
estradiols		I-IUPAC
.		O
Compound		O
33		O
and		O
its		O
analogues		O
did		O
not		O
inhibit		O
AChE		O
.		O
Selective		O
N		O
-		O
acetylation		O
and		O
subsequent		O
Friedel		O
-		O
Crafts		O
acylation		O
with		O
phthalic		O
anhydride		O
produced		O
2		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
5,12		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
azanaphthacene		I-IUPAC
-		I-IUPAC
6,11		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
,		O
which		O
was		O
protected		O
as		O
its		O
dimethyl		O
ether		O
and		O
epoxidized		O
to		O
an		O
acylated		O
aza		O
Brigl		O
's		O
anhydride		O
.		O
Such		O
inhibitors		O
may		O
be		O
useful		O
in		O
elucidating		O
the		O
physiological		O
and		O
pathological		O
events		O
involving		O
these		O
proteases		O
and		O
may		O
become		O
possible		O
therapeutic		O
agents		O
.		O
Efforts		O
to		O
improve		O
the		O
potency		O
of		O
the		O
title		O
series		O
by		O
variation		O
of		O
the		O
amide		O
,		O
indole		O
,		O
or		O
sulfonamide		O
substituents		O
led		O
to		O
compounds		O
of		O
comparable		O
in		O
vitro		O
potency		O
to		O
ICI		O
204,219		O
,		O
but		O
of		O
somewhat		O
lower		O
oral		O
activity		O
.		O
Both		O
isomers		O
were		O
hydrolyzed		O
by		O
NTPDase		O
1		O
at		O
about		O
half		O
the		O
rate		O
of		O
ATP		O
hydrolysis		O
.		O
In		O
previous		O
studies		O
,		O
we		O
reported		O
that		O
certain		O
(		B-PARTIUPAC
1R		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
(		O
substituted		B-MODIFIER
phenyl		B-IUPAC
)		O
nortropane		B-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
carboxylic		I-PARTIUPAC
acid		I-PARTIUPAC
methyl		I-PARTIUPAC
esters		I-PARTIUPAC
(		O
2a		O
)		O
exhibited		O
high		O
affinity		O
and		O
reasonable		O
selectivity		O
for		O
the		O
serotonin		O
transporter		O
(		O
5		O
-		O
HTT		O
)		O
.		O
These		O
discrepancies		O
may		O
reflect		O
different		O
selectivities		O
among		O
delta		O
receptor		O
subtypes		O
for		O
the		O
analogues		O
or		O
may		O
represent		O
differing		O
efficacies		O
among		O
these		O
conformationally		O
restricted		O
peptides		O
.		O
The		O
configuration		O
at		O
the		O
C		O
-		O
5		O
and		O
C		O
-		O
6		O
positions		O
also		O
influenced		O
potency		O
where		O
the		O
activity		O
of		O
the		O
5R		O
,		O
6R		O
-		O
diastereomer		O
was		O
generally		O
greater		O
than		O
that		O
of		O
the		O
corresponding		O
5S		O
,		O
6S		O
-		O
diastereomer		O
.		O
Interestingly		O
,		O
the		O
K		O
(		O
m		O
)		O
value		O
found		O
for		O
NOS		O
II		O
-		O
catalyzed		O
oxidation		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
hydroxyguanidine		I-IUPAC
was		O
25		O
microM		O
,		O
almost		O
identical		O
to		O
that		O
of		O
NOHA		O
.		O
This		O
paper		O
presents		O
the		O
structure		O
-		O
activity		O
relationships		O
leading		O
to		O
novel		O
tri		B-MODIFIER
-		I-MODIFIER
and		O
tetrasubstituted		B-MODIFIER
guanidines		B-IUPAC
,		O
which		O
exhibit		O
high		O
selectivity		O
for		O
NMDA		O
receptor		O
ion		O
channel		O
sites		O
and		O
weak		O
or		O
negligible		O
affinity		O
for		O
sigma		O
receptors		O
.		O
The		O
structures		O
of		O
the		O
new		O
analogues		O
are		O
as		O
follows		O
:		O
[		O
des		O
-		O
His1		O
,		O
des		O
-		O
Phe6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
1		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
Ala6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
2		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
Tyr6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
3		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
Trp6		O
,		O
Glu9		O
]		O
-		O
glucagon		O
-		O
NH2		O
(		O
4		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
D		O
-		O
Phe6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
5		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
Nle6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
6		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
Asp6		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
7		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
des		O
-		O
Gly4		O
,		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
8		O
)		O
;		O
[		O
desPhe6		O
,		O
-		O
Glu9		O
]		O
glucagon		O
-		O
NH2		O
(		O
9		O
)		O
;		O
[		O
des		O
-		O
Phe6		O
]		O
glucagon		O
-		O
NH2		O
(		O
10		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
des		O
-		O
Phe6		O
]		O
glucagon		O
-		O
NH2		O
(		O
11		O
)		O
;		O
[		O
des		O
-		O
His1		O
,		O
des		O
-		O
Phe6		O
,		O
Glu9		O
]		O
glucagon		O
(		O
12		O
)		O
;		O
[		O
des		O
-		O
Phe6		O
,		O
Glu9		O
]		O
glucagon		O
(		O
13		O
)		O
;		O
[		O
des		O
-		O
Phe6		O
]		O
glucagon		O
(		O
14		O
)		O
;		O
and		O
[		O
des		O
-		O
His1		O
,		O
des		O
-		O
Phe6		O
]		O
glucagon		O
(		O
15		O
)		O
.		O
sigma		O
-		O
Receptor		O
binding		O
affinities		O
were		O
obtained		O
using		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pentazocine		I-IUPAC
in		O
guinea		O
pig		O
brain		O
membrane		O
sigma		O
1		O
sites		O
.		O
Moderate		O
5-10		O
-		O
fold		O
selectivity		O
for		O
T		O
.		O
gondii		O
enzyme		O
relative		O
to		O
the		O
rat		O
liver		O
enzyme		O
.		O
The		O
distance		O
between		O
the		O
gem		O
-		O
dimethyl		O
group		O
and		O
the		O
terminal		O
carboxylate		O
appears		O
to		O
be		O
too		O
short		O
to		O
activate		O
the		O
retinoid		O
receptor		O
.		O
The		O
sodium		O
salt		O
glycosylation		O
of		O
the		O
imidazo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
isothiazoles		I-IUPAC
proceeded		O
smoothly		O
,		O
giving		O
mixtures		O
of		O
N		O
-		O
4		O
and		O
N		O
-		O
6		O
regioisomers		O
in		O
generally		O
good		O
yields		O
.		O
Addition		O
of		O
2		O
to		O
a		O
2		O
-		O
fold		O
excess		O
of		O
the		O
reaction		O
product		O
of		O
1		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridone		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
HOPO		O
-		O
C		O
)		O
and		O
1,1		B-IUPAC
'		I-IUPAC
-		I-IUPAC
carbonyldiimidazole		I-IUPAC
(		O
CDI		O
)		O
in		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylformamide		I-IUPAC
(		O
DMF		O
)		O
and		O
deprotection		O
with		O
BBr3		O
gave		O
1,14		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydroxybenzoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,10		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridon		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
oyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,5,10,14		I-IUPAC
-		I-IUPAC
tetraaza		I-IUPAC
-		I-IUPAC
tetradecane		I-IUPAC
[		O
3		O
,		O
3,4,3		O
-		O
LI		O
(		O
diCAM		O
-		O
diHOPO		O
)		O
]		O
in		O
5%		O
yield		O
.		O
4alpha		B-IUPAC
,		I-IUPAC
19		I-IUPAC
-		I-IUPAC
Diol		I-IUPAC
25		O
was		O
synthesized		O
from		O
tert		B-IUPAC
-		I-IUPAC
butyldimethylsilyoxyandrost		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
steroid		B-MODIFIER
(		O
9		O
)		O
through		O
its		O
OsO		O
(		O
4		O
)		O
oxidation		O
,		O
giving		O
the		O
4alpha		B-IUPAC
,		I-IUPAC
5alpha		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
derivative		B-MODIFIER
12		O
,		O
as		O
a		O
key		O
reaction		O
.		O
The		O
electron		O
-		O
withdrawing		O
chloroethyl		B-IUPAC
group		B-MODIFIER
at		O
the		O
endocyclic		O
and		O
/		O
or		O
exocyclic		O
nitrogens		O
counteracts		O
the		O
endocyclic		O
P		O
-		O
N		O
bond		O
hydrolysis		O
.		O
Racemic		O
6		O
,		O
but		O
not		O
11		O
,		O
partially		O
substituted		O
for		O
LSD		O
.		O
Like		O
the		O
parent		O
compound		O
4a		O
(		O
IC50		O
=		O
0.18		O
microM		O
)		O
,		O
4c		O
(		O
IC50		O
=		O
0.18		O
microM		O
)		O
,		O
4e		O
(		O
IC50		O
=		O
0.14		O
microM		O
)		O
,		O
and		O
in		O
particular		O
4d		O
(		O
IC50		O
=		O
0.02		O
microM		O
)		O
were		O
effective		O
inhibitors		O
of		O
calcium		O
chloride		O
-		O
dependent		O
[		O
3H		O
]		O
glutamic		O
acid		O
binding		O
,		O
whereas		O
AMPA		O
is		O
inactive		O
(		O
IC50		O
greater		O
than		O
100		O
microM		O
)		O
in		O
this		O
binding		O
assay		O
.		O
Compound		O
9f		O
displayed		O
significant		O
activity		O
against		O
rhinovirus		O
type		O
34		O
grown		O
in		O
WISH		O
cells		O
.		O
Careful		O
analysis		O
of		O
the		O
NMR		O
structures		O
of		O
cyclo		O
(		O
4-10		O
)		O
[		O
Ac		O
-		O
Delta		O
(		O
3		O
)		O
Pro		O
(		O
1		O
)		O
,		O
DFpa		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
3		O
)		O
,		O
Asp		O
(		O
4		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
Dpr		O
(		O
10		O
)		O
]		O
GnRH		O
,		O
dicyclo		O
(		O
4-10/5-8		O
)		O
[		O
Ac		O
-		O
DNal		O
(		O
1		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
3		O
)		O
,		O
Asp		O
(		O
4		O
)		O
,		O
Glu		O
(		O
5		O
)		O
,		O
DArg		O
(		O
6		O
)		O
,		O
Lys		O
(		O
8		O
)		O
,		O
Dpr		O
(		O
10		O
)		O
]		O
GnRH		O
,		O
and		O
dicyclo		O
(		O
4-10/5		O
,		O
5'		O
-		O
8		O
)		O
[		O
Ac		O
-		O
DNal		O
(		O
1		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DPal		O
(		O
3		O
)		O
,		O
Asp		O
(		O
4		O
)		O
,		O
Glu		O
(		O
5		O
)		O
(		O
Gly		O
)		O
,		O
DArg		O
(		O
6		O
)		O
,		O
Dbu		O
(		O
8		O
)		O
,		O
Dpr		O
(		O
10		O
)		O
]		O
GnRH		O
showed		O
that		O
,		O
in		O
the		O
N		O
-		O
terminal		O
tripeptide		O
,		O
a		O
type		O
II		O
beta		O
-		O
turn		O
around		O
residues		O
1		O
and		O
2		O
was		O
probable		O
along		O
with		O
a		O
gamma		O
-		O
turn		O
around		O
DTrp		O
(		O
3		O
)		O
/		O
DPal		O
(		O
3		O
)		O
.		O
The		O
ability		O
of		O
the		O
dihydrodiols		O
3a		O
-		O
c		O
and		O
the		O
trans		B-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydrodiol		I-IUPAC
of		O
7,12		B-IUPAC
-		I-IUPAC
dimethylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
3d		O
)		O
to		O
induce		O
chromosomal		O
aberrations		O
in		O
rat		O
bone		O
marrow		O
cells		O
was		O
also		O
examined		O
.		O
Side		O
-		O
chain		O
protection		O
of		O
Trp		O
by		O
the		O
Boc		O
group		O
was		O
found		O
to		O
preserve		O
Trp		O
integrity		O
during		O
Tl		O
(		O
Tfa		O
)		O
3		O
treatment		O
.		O
Analogues		O
1-9		O
and		O
14		O
are		O
potent		O
AVP		O
V1		O
antagonists		O
.		O
We		O
have		O
previously		O
described		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
6H		I-IUPAC
-		I-IUPAC
cyclohepta		I-IUPAC
[		I-IUPAC
d		I-IUPAC
]		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
4		O
-		O
AHCP		O
)		O
as		O
a		O
highly		O
effective		O
agonist		O
at		O
non		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
d		I-IUPAC
-		I-IUPAC
aspartate		I-IUPAC
(		O
non		O
-		O
NMDA		O
)		O
glutamate		O
(		O
Glu		O
)		O
receptors		O
in		O
vivo		O
,		O
which		O
is		O
more		O
potent		O
than		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
)		O
but		O
inactive		O
at		O
NMDA		O
receptors		O
.		O
In		O
the		O
series		O
of		O
indoles		O
4		O
,		O
the		O
introduction		O
of		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
on		O
the		O
benzylic		O
carbon		O
with		O
the		O
R		O
configuration		O
improved		O
affinity		O
of		O
the		O
5		O
-		O
substituted		O
(		O
5		O
-		O
Cl		O
and		O
5		O
-		O
NO		O
(		O
2		O
)		O
)		O
derivatives		O
,		O
whereas		O
it		O
was		O
detrimental		O
for		O
their		O
5		O
-		O
unsubtituted		O
(		O
5		O
-		O
H		O
)		O
counterparts		O
.		O
A		O
series		O
of		O
complexes		O
of		O
the		O
general		O
formula		O
trans		O
-		O
[		O
PtCl2		O
(		O
Am		O
)		O
(		O
pip		O
-		O
pip		O
)		O
]		O
x		O
HCl		O
where		O
pip		O
-		O
pip		O
is		O
4		B-IUPAC
-		I-IUPAC
piperidinopiperidine		I-IUPAC
and		O
Am		O
is		O
NH3		O
,		O
methylamine		O
(		O
MA		O
)		O
,		O
dimethylamine		B-IUPAC
(		O
DMA		O
)		O
,		O
n		B-IUPAC
-		I-IUPAC
propylamine		I-IUPAC
(		O
NPA		O
)		O
,		O
isopropylamine		O
(		O
IPA		O
)		O
,		O
n		B-IUPAC
-		I-IUPAC
butylamine		I-IUPAC
(		O
NBA		O
)		O
,		O
or		O
cyclohexylamine		B-IUPAC
(		O
CHA		O
)		O
were		O
prepared		O
and		O
characterized		O
,		O
and		O
their		O
cytotoxic		O
properties		O
against		O
ovarian		O
and		O
colon		O
cancer		O
cells		O
were		O
evaluated		O
.		O
In		O
some		O
cases		O
,		O
the		O
positional		O
isomers		O
6		O
and		O
8		O
were		O
also		O
obtained		O
.		O
5		B-IUPAC
-		I-IUPAC
Formyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
9		O
)		O
and		O
its		O
dithiolane		B-IUPAC
derivative		B-MODIFIER
11		O
were		O
prepared		O
by		O
condensation		O
of		O
the		O
bis		B-IUPAC
(		I-IUPAC
trimethylsilyl		I-IUPAC
)		I-IUPAC
derivative		B-MODIFIER
of		O
5		B-IUPAC
-		I-IUPAC
formyluracil		I-IUPAC
dimethyl		I-IUPAC
acetal		I-IUPAC
and		O
the		O
protected		O
chloro		O
sugar		O
followed		O
by		O
saponification		O
of		O
the		O
protective		O
groups		O
.		O
Scatchard		O
analyses		O
of		O
binding		O
to		O
brain		O
sections		O
revealed		O
heterogeneous		O
binding		O
profiles		O
for		O
both		O
antagonists		O
,		O
suggesting		O
the		O
presence		O
of		O
multiple		O
receptor		O
binding		O
sites		O
.		O
At		O
the		O
5		O
-		O
position		O
,		O
a		O
homologous		O
series		O
of		O
phenylalkyl		O
esters		O
and		O
a		O
series		O
of		O
substituted		B-MODIFIER
benzyl		B-IUPAC
esters		I-IUPAC
were		O
prepared		O
and		O
tested		O
.		O
cis		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
Benzyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylpyrrolidin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
benzamide		I-IUPAC
(		O
YM		O
-		O
09151-2		O
,		O
55		O
)		O
was		O
the		O
most		O
active		O
among		O
all		O
of		O
the		O
compounds		O
tested		O
,		O
being		O
13		O
and		O
408		O
times		O
more		O
potent		O
than		O
haloperidol		O
and		O
metoclopramide		O
,		O
respectively		O
.		O
In		O
this		O
displacement		O
assay		O
,		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pentazocine		I-IUPAC
exhibited		O
a		O
Ki		O
of		O
3.1		O
nM		O
while		O
DTG		O
and		O
haloperidol		O
showed		O
Ki		O
values		O
of		O
27.7		O
and		O
3.7		O
nM		O
,		O
respectively		O
.		O
)		O
.		O
The		O
model		O
can		O
also		O
account		O
for		O
the		O
binding		O
of		O
quinoxaline		B-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
,		O
quinoxalic		B-IUPAC
acids		I-IUPAC
,		O
and		O
2		B-IUPAC
-		I-IUPAC
carboxybenzimidazoles		I-IUPAC
.		O
The		O
(		O
1R		O
,		O
2R		O
)		O
-		O
(		O
+		O
)		O
-		O
enantiomer		O
,		O
(		O
+		O
)		O
-		O
2		O
,		O
had		O
low		O
affinity		O
for		O
both		O
kappa		O
and		O
sigma		O
receptors		O
,		O
exhibiting		O
Ki		O
values		O
of		O
1298		O
+		O
/		O
-		O
49		O
nM		O
at		O
kappa		O
(		O
[		O
3H		O
]		O
BREM		O
)		O
and		O
1270		O
+		O
/		O
-		O
168		O
nM		O
at		O
sigma		O
[		O
[		O
3H		O
]		O
-		O
(		O
+		O
)		O
-		O
3		O
-		O
PPP		O
]		O
.		O
Appropriately		O
substituted		O
2,3		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
7H		I-IUPAC
-		I-IUPAC
thiazolo		I-IUPAC
[		I-IUPAC
3,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
9-12		O
and		O
18		O
were		O
considered		O
as		O
annulated		O
analogues		O
of		O
HEPT		O
(		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
thymine		I-IUPAC
)		O
,		O
and		O
some		O
of		O
these		O
compounds		O
were		O
also		O
found		O
active		O
against		O
HIV		O
-		O
1		O
,		O
the		O
most		O
active		O
one		O
being		O
2,3		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dimethylphenyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
7H		I-IUPAC
-		I-IUPAC
thiazolo		I-IUPAC
[		I-IUPAC
3,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
10b		O
)		O
.		O
These		O
agents		O
were		O
evaluated		O
in		O
vitro		O
and		O
in		O
vivo		O
for		O
their		O
ability		O
to		O
suppress		O
HMG		O
CoA		O
reductase		O
,		O
the		O
rate		O
-		O
limiting		O
enzyme		O
of		O
cholesterol		O
biosynthesis		O
.		O
Synthetic		O
yields		O
were		O
insufficient		O
for		O
chemical		O
investigations		O
or		O
evaluation		O
of		O
acute		O
toxicity		O
.		O
In		O
a		O
structure		O
-		O
activity		O
comparison		O
it		O
was		O
found		O
that		O
at		O
optimum		O
dose		O
all		O
compounds		O
containing		O
the		O
nitroxyl		O
radical		O
were		O
more		O
active		O
than		O
the		O
corresponding		O
hydroxylamine		O
derivatives		O
.		O
The		O
benzyl		B-IUPAC
ether		I-IUPAC
functions		B-MODIFIER
of		O
7		O
and		O
9		O
were		O
removed		O
with		O
boron		O
trichloride		O
to		O
afford		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabinofuranosyl		I-IUPAC
)		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyridazin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
8		O
)		O
and		O
its		O
3		O
-		O
bromo		O
analog		O
10		O
.		O
The		O
2'		O
-		O
substituent		O
was		O
also		O
a		O
determinant		O
of		O
cytotoxic		O
activity		O
in		O
the		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethyl		I-IUPAC
)		I-IUPAC
(		O
11a		O
-		O
c		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethyl		I-IUPAC
)		I-IUPAC
series		B-MODIFIER
of		O
compounds		O
,		O
where		O
the		O
relative		O
activity		O
profile		O
was		O
2'		B-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
greater		O
than		O
2'		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
greater		O
than		O
uridine		B-IUPAC
(		O
11a		O
greater		O
than		O
11b		O
greater		O
than		O
or		O
equal		O
to		O
11c		O
;		O
12a		O
greater		O
than		O
12b		O
greater		O
than		O
12c		O
)		O
.		O
It		O
gave		O
100%		O
protection		O
against		O
PAF		O
-		O
induced		O
mortality		O
in		O
mice		O
7		O
h		O
after		O
i		O
.		O
Several		O
series		O
of		O
2,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2,4,5		I-IUPAC
-		O
trisubstituted		B-MODIFIER
-		O
3H		B-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
with		O
acidic		O
sulfonamide		O
replacements		O
of		O
tetrazole		O
at		O
the		O
2'		O
-		O
position		O
of		O
the		O
biphenyl		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
at		O
N4		O
were		O
prepared		O
and		O
tested		O
as		O
angiotensin		O
II		O
(		O
AII		O
)		O
antagonists		O
.		O
Several		O
series		O
of		O
N6		O
-		O
or		O
8		O
-		O
substituted		O
derivatives		O
of		O
adenosine		B-IUPAC
5'		I-IUPAC
-		I-IUPAC
triphosphate		I-IUPAC
(		O
ATP		O
)		O
were		O
synthesized		O
.		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
Di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylamino		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
indolone		I-IUPAC
was		O
the		O
most		O
potent		O
compound		O
(		O
ED50		O
=		O
2		O
+		O
/		O
-		O
0.3		O
nM		O
)		O
tested		O
,		O
while		O
the		O
related		O
secondary		O
amine		O
24		O
and		O
the		O
des		O
-		O
OH		O
derivatives		O
28		O
and		O
34		O
were		O
only		O
slightly		O
less		O
potent		O
.		O
The		O
interaction		O
of		O
indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
with		O
DNA		O
was		O
studied		O
by		O
measuring		O
the		O
increase		O
of		O
calf		O
thymus		O
DNA		O
denaturating		O
temperature		O
(		O
Tm		O
)		O
.		O
Analogously		O
,		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxypyrimidine		I-IUPAC
gave		O
on		O
reaction		O
with		O
[		O
(		B-PARTIUPAC
R		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
diisopropylphosphorylmethoxy		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		O
tosylate		B-MODIFIER
,		O
followed		O
by		O
deprotection		O
,		O
the		O
enantiomeric		O
6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
propoxy		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
.		O
None		O
of		O
the		O
indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
belonging		O
to		O
the		O
6H		O
series		O
,		O
i.e.		O
,		O
lacking		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
on		O
the		O
pyridine		O
nitrogen		O
,		O
was		O
active		O
in		O
analogous		O
tests		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
cyanamido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
haloethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridines		I-IUPAC
(		O
4-6		O
)		O
all		O
were		O
approximately		O
equipotent		O
against		O
HSV		O
-		O
2		O
and		O
were		O
approximately		O
1.5		O
-		O
and		O
15		O
-		O
fold		O
less		O
inhibitory		O
for		O
HSV		O
-		O
2		O
than		O
EDU		O
and		O
acyclovir		O
,		O
respectively		O
.		O
The		O
activity		O
of		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethoxycarbonyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
thiophene		I-IUPAC
,		O
10h		O
(		O
26%		O
)		O
,		O
is		O
an		O
exception		O
to		O
the		O
rule		O
that		O
a		O
3		B-IUPAC
-		I-IUPAC
ethoxycarbonyl		I-IUPAC
substituent		B-MODIFIER
cannot		O
support		O
AE		O
activity		O
.		O
It		O
was		O
selected		O
from		O
a		O
large		O
series		O
of		O
(		B-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
piperidinyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
ethanones		I-IUPAC
synthesized		O
by		O
a		O
modified		O
Schopf		O
reaction		O
from		O
enolate		O
magnesium		O
salts		O
of		O
beta		O
-		O
keto		O
acids		O
and		O
2,3,4,5		B-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
trimer		B-MODIFIER
or		O
3,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
pyrrole		I-IUPAC
trimer		B-MODIFIER
,		O
respectively		O
.		O
The		O
comparable		O
potency		O
and		O
spectrum		O
of		O
activity		O
of		O
juncusol		O
(		O
1a		O
)		O
,		O
desvinyljuncusol		O
(		O
2h		O
)		O
,		O
and		O
2		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
9,10		I-IUPAC
-		I-IUPAC
dihydrophenanthrene		I-IUPAC
(		O
3h		O
)		O
suggest		O
that		O
the		O
agents		O
are		O
acting		O
as		O
simple		O
phenols		O
in		O
exerting		O
their		O
antimicrobial		O
and		O
cytotoxic		O
effects		O
.		O
An		O
enantiospecific		O
method		O
was		O
developed		O
for		O
the		O
synthesis		O
of		O
3		B-PARTIUPAC
-		I-PARTIUPAC
fluoromethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
hydroxymethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
chloromethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		O
substituted		B-MODIFIER
-		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydroisoquinolines		I-IUPAC
(		O
THIQs		O
)		O
from		O
phenylalanine		O
.		O
In		O
the		O
ODC		O
assay		O
,		O
systems		O
1a		O
-		O
c		O
exhibited		O
strong		O
activity		O
(		O
within		O
10%		O
of		O
or		O
less		O
than		O
the		O
control		O
)		O
whereas		O
alcohols		O
2b		O
and		O
3a		O
showed		O
good		O
activity		O
(		O
within		O
50%		O
of		O
the		O
control		O
)		O
as		O
compared		O
to		O
either		O
13		B-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
retinoic		I-IUPAC
acid		I-IUPAC
or		O
trans		B-IUPAC
-		I-IUPAC
retinoic		I-IUPAC
acid		I-IUPAC
.		O
Med.		O
Chem.		O
1998		O
,		O
41		O
,		O
1752		O
)		O
,		O
where		O
the		O
3		O
-		O
aza		O
and		O
2		O
-		O
NH		O
atoms		O
form		O
a		O
bidentate		O
H		O
-		O
bond		O
donor		O
-		O
acceptor		O
motif		O
that		O
interacts		O
with		O
Met341		O
and		O
the		O
1		O
-		O
aza		O
atom		O
is		O
not		O
involved		O
in		O
specific		O
binding		O
interactions		O
.		O
In		O
the		O
phototolerance		O
model		O
,		O
the		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
quinolones		I-IUPAC
are		O
comparable		O
to		O
the		O
8H		B-IUPAC
-		I-IUPAC
quinolones		I-IUPAC
.		O
A		O
detailed		O
NMR		O
analysis		O
with		O
restrained		O
and		O
free		O
molecular		O
dynamics		O
calculations		O
in		O
explicit		O
H		O
(		O
2		O
)		O
O		O
exhibits		O
a		O
well		O
-		O
defined		O
structure		O
with		O
characteristic		O
features		O
such		O
as		O
an		O
omega		O
-		O
loop		O
with		O
two		O
betaI		O
-		O
turns		O
about		O
Lys		O
(		O
3		O
)		O
,		O
Tyr		O
(		O
4		O
)		O
,		O
Ser		O
(		O
6		O
)		O
,		O
and		O
Asn		O
(		O
7		O
)		O
.		O
Cystazosin		O
(		O
3		O
)		O
,		O
bearing		O
a		O
cystamine		O
moiety		O
,		O
was		O
a		O
selective		O
alpha1D		O
-		O
adrenoreceptor		O
antagonist		O
being		O
1		O
order		O
of		O
magnitude		O
more		O
potent		O
at		O
alpha1D		O
-		O
adrenoreceptors		O
(		O
pA2		O
,		O
8.54		O
+		O
/		O
-		O
0.02		O
)		O
than		O
at		O
the		O
alpha1A		O
-		O
(		O
pA2		O
,		O
7.53		O
+		O
/		O
-		O
0.01		O
)		O
and		O
alpha1B		O
-		O
subtypes		O
(		O
pA2		O
,		O
7.49		O
+		O
/		O
-		O
0		O
.		O
In		O
order		O
to		O
explore		O
the		O
use		O
of		O
this		O
REV		O
to		O
account		O
for		O
the		O
activities		O
of		O
other		O
cannabinoids		O
,		O
the		O
minimally		O
active		O
classical		O
cannabinoid		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
hexahydrocannabinol		I-IUPAC
,		O
an		O
active		O
benzofuran		O
cannabinoid		O
,		O
and		O
the		O
active		O
nonclassical		O
cannabinoid		O
CP		O
-		O
47,497		O
were		O
then		O
studied		O
.		O
Sulfenylation		O
of		O
3		O
with		O
NPS		O
-		O
Cl		O
gave		O
Z		O
-		O
Lys		O
(		O
Z		O
)		O
-		O
Trp		O
(		O
NPS		O
)		O
-		O
OMe		O
,		O
which		O
,		O
on		O
catalytic		O
hydrogenation		O
of		O
the		O
nitro		O
group		O
using		O
10%		O
Pd		O
/		O
C		O
followed		O
by		O
acetylation		O
of		O
the		O
resulting		O
amino		O
function		O
and		O
removal		O
of		O
the		O
protecting		O
Z		O
groups		O
,		O
gave		O
17		O
.		O
The		O
final		O
products		O
were		O
tested		O
in		O
vitro		O
as		O
inhibitors		O
of		O
DHFR		O
from		O
Pneumocystis		O
carinii		O
,		O
Toxoplasma		O
gondii		O
,		O
rat		O
liver		O
,		O
beef		O
liver		O
,		O
and		O
Lactobacillus		O
casei		O
.		O
Although		O
analgesic		O
activities		O
of		O
sulfur		O
-		O
containing		O
benzazocines		O
decreased		O
compared		O
to		O
the		O
corresponding		O
hydroxy		O
compounds		O
,		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
derivative		B-MODIFIER
(		O
S		O
-		O
metazocine		O
,		O
8		O
)		O
showed		O
potent		O
analgesic		O
activity		O
.		O
No		O
analgesia		O
was		O
however		O
found		O
with		O
the		O
phenylsulfenyl		O
or		O
acyclic		O
sulfenyl		O
substituted		O
dipeptides		O
9		O
,		O
11		O
,		O
and		O
17		O
or		O
13		O
,		O
23		O
,		O
and		O
24		O
.		O
Optimization		O
of		O
the		O
activity		O
in		O
this		O
series		O
resulted		O
in		O
the		O
development		O
of		O
5		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
benzylcarboxamides		I-IUPAC
(		O
30		O
)		O
which		O
are		O
highly		O
potent		O
orally		O
active		O
NK1		O
antagonists		O
.		O
One		O
compound		O
(		O
5j		O
)		O
had		O
an		O
IC50		O
of		O
&		O
lt		O
;		O
0.01		O
microM		O
against		O
four		O
of		O
the		O
cell		O
lines		O
.		O
Several		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
arylalkylpolyamines		I-IUPAC
containing		O
various		O
aromatic		O
ring		O
systems		O
were		O
synthesized		O
as		O
their		O
respective		O
HCl		O
salts		O
.		O
Several		O
N		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
hydroxyguanidines		I-IUPAC
bearing		O
a		O
relatively		O
small		O
,		O
electron		O
-		O
donating		O
para		O
subtituent		O
,		O
such		O
as		O
H		O
,		O
F		O
,		O
Cl		O
,		O
CH		O
(		O
3		O
)		O
,		O
OH		O
,		O
OCH		O
(		O
3		O
)		O
,		O
and		O
NH		O
(		O
2		O
)		O
,		O
led		O
to		O
NO		O
formation		O
rates		O
between		O
8		O
and		O
41%		O
of		O
that		O
of		O
NO		O
formation		O
from		O
the		O
natural		O
NOS		O
substrate		O
,		O
N		B-IUPAC
(		I-IUPAC
omega		I-IUPAC
)		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
(		O
NOHA		O
)		O
.		O
Qualitative		O
correlation		O
between		O
the		O
sigma		O
and		O
PCP		O
binding		O
data		O
suggests		O
some		O
similarities		O
between		O
these		O
binding		O
sites		O
.		O
The		O
affinities		O
and		O
the		O
GABA		O
ratios		O
of		O
selected		O
compounds		O
for		O
clonal		O
mammalian		O
alpha		O
(		O
1		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2		O
)		O
,		O
alpha		O
(		O
3		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2		O
)		O
,		O
and		O
alpha		O
(		O
5		O
)		O
beta		O
(		O
3		O
)		O
gamma		O
(		O
2		O
)		O
BzR		O
subtypes		O
were		O
also		O
determined		O
.		O
However		O
,		O
several		O
of		O
the		O
BTCP		O
-		O
related		O
derivatives		O
showed		O
greater		O
(		O
compared		O
with		O
BTCP		O
and		O
cocaine		O
)		O
ability		O
to		O
displace		O
[		O
3H		O
]		O
cocaine		O
.		O
Several		O
analogs		O
exhibited		O
moderate		O
to		O
very		O
good		O
growth		O
inhibitory		O
activities		O
against		O
cultured		O
L1210		O
leukemia		O
and		O
6410		O
human		O
leukemic		O
myeloblasts		O
.		O
(		O
125		O
)		O
Iodinated		O
19		O
selectively		O
binds		O
to		O
sst		O
(		O
4		O
)		O
-		O
transfected		O
cells		O
but		O
not		O
to		O
sst		O
(		O
1-3		O
)		O
-		O
or		O
sst		O
(		O
5		O
)		O
-		O
transfected		O
cells		O
.		O
The		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2,5		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
imidazolidinone		I-IUPAC
has		O
high		O
affinity		O
for		O
5		O
-		O
HT2		O
receptors		O
(		O
IC50		O
=		O
3.4		O
nM		O
)		O
and		O
extremely		O
low		O
affinity		O
for		O
both		O
dopamine		O
D2		O
receptors		O
(		O
IC50		O
=		O
6900		O
nM		O
)		O
and		O
alpha		O
1		O
adrenoceptors		O
(		O
IC50		O
=		O
2300		O
nM		O
)		O
.		O
(		O
all		O
-		O
E		O
)		O
-		O
1		O
and		O
(		O
13Z		O
)		O
-		O
1		O
were		O
both		O
shown		O
to		O
be		O
equally		O
effective		O
as		O
(		B-IUPAC
13Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
retinoic		I-IUPAC
acid		I-IUPAC
in		O
suppressing		O
the		O
proliferation		O
of		O
human		O
sebaceous		O
cells		O
in		O
vitro		O
.		O
Examination		O
of		O
initial		O
rate		O
kinetics		O
of		O
carbonic		O
anhydrase		O
catalyzed		O
p		B-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
acetate		I-IUPAC
hydrolysis		O
showed		O
that		O
N		B-IUPAC
-		I-IUPAC
methylacetazolamide		I-IUPAC
was		O
a		O
competitive		O
inhibitor		O
,		O
in		O
contrast		O
to		O
noncompetitive		O
inhibition		O
seen		O
with		O
acetazolamide		O
and		O
other		O
primary		O
sulfonamide		O
inhibitors		O
.		O
On		O
the		O
other		O
hand		O
,		O
all		O
compounds		O
were		O
less		O
effective		O
than		O
DA		O
in		O
stimulation		O
of		O
adenylate		O
cyclase		O
activity		O
in		O
rat		O
striatal		O
homogenates		O
,		O
a		O
kind		O
of		O
effect		O
which		O
is		O
mediated		O
by		O
the		O
D		O
-		O
1		O
subtype		O
of		O
DA		O
receptors		O
.		O
;		O
et		O
al.		O
J		O
.		O
The		O
best		O
of		O
these		O
compounds		O
generally		O
had		O
a		O
methyl		O
group		O
at		O
the		O
N1		O
position		O
,		O
a		O
[		B-IUPAC
(		I-IUPAC
cyclopentyloxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
or		O
2		B-IUPAC
-		I-IUPAC
cyclopentylacetamido		I-IUPAC
or		O
N'		B-IUPAC
-		I-IUPAC
cyclopentylureido		I-IUPAC
group		B-MODIFIER
at		O
the		O
C		O
-		O
5		O
position		O
,		O
and		O
an		O
arylsulfonyl		O
amide		O
group		O
as		O
part		O
of		O
the		O
acidic		O
chain		O
at		O
the		O
C		O
-		O
3		O
position		O
of		O
the		O
ring		O
.		O
This		O
article		O
is		O
the		O
first		O
report		O
of		O
structure		O
-		O
activity		O
relationships		O
(		O
SAR		O
)		O
concerning		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptor		O
agonists		O
as		O
agents		O
for		O
the		O
treatment		O
of		O
urinary		O
frequency		O
and		O
incontinence		O
.		O
It		O
is		O
likely		O
that		O
they		O
exert		O
their		O
antiviral		O
effect		O
via		O
selective		O
inhibition		O
of		O
the		O
methyltransferases		O
which		O
are		O
required		O
for		O
the		O
maturation		O
of		O
viral		O
mRNAs		O
.		O
A		O
series		O
of		O
gallium		O
(		O
III		O
)		O
and		O
iron		O
(		O
III		O
)		O
complexes		O
with		O
five		O
different		O
4N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
alpha		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
heterocyclic		I-IUPAC
thiosemicarbazones		I-IUPAC
,		O
viz		O
.		O
The		O
ratios		O
IC50		O
(		O
[		O
3H		O
]		O
cocaine		O
)		O
/		O
IC50		O
(		O
[		O
3H		O
]		O
BTCP		O
)		O
ranged		O
from		O
62		O
for		O
BTCP		O
to		O
1.5		O
for		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyclopentylamine		I-IUPAC
(		O
17		O
)		O
;		O
cocaine		O
gave		O
a		O
ratio		O
of		O
0.6		O
.		O
gondii		O
tachyzoites		O
in		O
culture		O
and		O
were		O
found		O
to		O
have		O
a		O
potency		O
(		O
IC50		O
=		O
0.1-0.5		O
microM		O
)		O
similar		O
to		O
that		O
of		O
pyrimethamine		O
(		O
IC50		O
=		O
0.69		O
microM		O
)		O
,		O
a		O
standard		O
clinical		O
agent		O
for		O
the		O
treatment		O
of		O
cerebral		O
toxoplasmosis		O
in		O
AIDS		O
patients		O
.		O
The		O
size		O
of		O
the		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
arylalkyl		I-IUPAC
substituent		B-MODIFIER
as		O
well		O
as		O
the		O
polyamine		O
sequence		O
used		O
had		O
direct		O
bearing		O
on		O
the		O
observed		O
cytotoxicity		O
profiles		O
.		O
E		O
.		O
[		O
1		O
-		O
N		O
-		O
Methylisoasparagine		O
,		O
8		O
-		O
isoleucine		O
]		O
-		O
(		O
I		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine		I-PARTIUPAC
,		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
methyltyrosine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
isoleucine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
II		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine		I-PARTIUPAC
,		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
methylisoleucine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
isoleucine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
III		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
methylisoleucine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
IV		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine8k		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
methylisoleucine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
methylisoleucine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
V		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
O		I-PARTIUPAC
-		I-PARTIUPAC
methylthreonine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
VI		O
)		O
,		O
[		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
sarcosine		I-PARTIUPAC
,		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
methionine		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
VII		O
)		O
,		O
and		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
serine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
(		O
VIII		O
)		O
,		O
synthesized		O
by		O
Merrifield		O
's		O
solid		O
-		O
phase		O
procedure		O
,		O
possess		O
respectively		O
0.8		O
,		O
0.3		O
,		O
0.5		O
,		O
1.0		O
,		O
0.0		O
,		O
0.5		O
,		O
3.7		O
,		O
and		O
0.7%		O
pressor		O
activity		O
of		O
angiotensin		O
II		O
(		O
vagotomized		O
,		O
ganglion		O
-		O
blocked		O
rats		O
)		O
.		O
Homo		O
-		O
AMPA		O
(		O
8		O
)		O
,		O
which		O
is		O
a		O
3		B-IUPAC
-		I-IUPAC
isoxazolol		I-IUPAC
bioisostere		B-MODIFIER
of		O
2		B-IUPAC
-		I-IUPAC
aminoadipic		I-IUPAC
acid		I-IUPAC
(		O
3		O
)		O
,		O
was		O
,		O
however		O
,		O
shown		O
to		O
be		O
a		O
specific		O
and		O
rather		O
potent		O
agonist		O
at		O
mGlu6		O
,		O
approximately		O
4		O
times		O
weaker		O
than		O
the		O
nonselective		O
excitatory		O
amino		O
acid		O
receptor		O
agonist		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
.		O
The		O
binding		O
affinities		O
of		O
21		O
at		O
alpha		O
(		O
1		O
)		O
-		O
adrenergic		O
receptors		O
(		O
[		B-IUPAC
(		I-IUPAC
3		I-IUPAC
)		I-IUPAC
H		I-IUPAC
]		I-IUPAC
prazosin		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
0.54		O
microM		O
)		O
and		O
dopamine		O
D2		O
receptors		O
(		O
[		B-IUPAC
(		I-IUPAC
3		I-IUPAC
)		I-IUPAC
H		I-IUPAC
]		I-IUPAC
raclopride		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
1.2		O
microM		O
)		O
are		O
reduced		O
by		O
incorporating		O
a		O
hydroxy		O
group		O
onto		O
the		O
4		O
-		O
position		O
of		O
the		O
piperidine		O
ring		O
and		O
the		O
beta		O
-		O
carbon		O
of		O
the		O
N		O
-		O
alkyl		O
spacer		O
to		O
give		O
(		O
+		O
/		O
-		O
)		O
-		O
27		O
:		O
IC		O
(		O
50		O
)		O
NR1A		O
/		O
2B		O
,		O
0.026		O
;		O
alpha		O
(		O
1		O
)		O
,		O
14		O
;		O
D2		O
,		O
105		O
microM		O
.		O
The		O
conformationally		O
free		O
parent		O
compound		O
1		O
exhibited		O
a		O
Ki		O
value		O
of		O
2.1		O
nM		O
.		O
Subsequent		O
modification		O
of		O
the		O
amino		O
terminal		O
into		O
N		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
led		O
to		O
the		O
most		O
potent		O
compound		O
,		O
N		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
threonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N1		I-IUPAC
-		I-IUPAC
formyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
tryptophyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
phenylalaninamide		I-IUPAC
[		O
Ac		O
-		O
Thr		O
-		O
D		O
-		O
Trp		O
(		O
CHO		O
)		O
-		O
Phe		O
-		O
NMeBzl		O
(		O
5a		O
,		O
FR113680		O
)		O
]		O
.		O
On		O
isolated		O
organs		O
pA2		O
values		O
(		O
rabbit		O
aortic		O
strips		O
)		O
of		O
8.74		O
,		O
7.44		O
,		O
7.64		O
,		O
7.85		O
,		O
7.89		O
,		O
8.76		O
,		O
8.63		O
,		O
and		O
8.08		O
,		O
and		O
pA2		O
values		O
(		O
cat		O
adrenal		O
medulla		O
of		O
8.16		O
,		O
9.16		O
,		O
9.31		O
,		O
8.00		O
,		O
8.00		O
,		O
7.00		O
,		O
9.16		O
,		O
and		O
9.33		O
were		O
obtained		O
.		O
A		O
dose		O
of		O
36		O
mg		O
/		O
kg		O
per		O
day		O
for		O
5		O
days		O
caused		O
no		O
toxic		O
deaths		O
while		O
the		O
average		O
tumor		O
volume		O
among		O
10		O
mice		O
was		O
reduced		O
to		O
8-9%		O
of		O
that		O
of		O
the		O
control		O
,		O
and		O
20%		O
of		O
the		O
test		O
animals		O
were		O
rendered		O
tumor		O
free		O
.		O
The		O
introduction		O
of		O
two		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
groups		B-MODIFIER
(		O
18a		O
)		O
on		O
the		O
nitrogen		O
atom		O
reduces		O
by		O
one		O
-		O
half		O
and		O
doubles		O
the		O
affinity		O
for		O
D		O
-		O
1		O
and		O
D		O
-		O
2		O
binding		O
sites		O
,		O
respectively		O
.		O
The		O
peptide		O
alpha		O
-		O
keto		O
amide		O
Z		O
-		O
Leu		O
-		O
Abu		O
-		O
CONH		O
-		O
(		O
CH2		O
)		O
2-3		O
-		O
indolyl		O
was		O
the		O
best		O
inhibitor		O
for		O
cathepsin		O
B		O
(		O
Ki		O
=		O
31		O
nM		O
)		O
.		O
In		O
a		O
continuing		O
effort		O
to		O
design		O
small		O
-		O
molecule		O
inhibitors		O
of		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
that		O
combine		O
the		O
enzyme		O
-		O
binding		O
selectivity		O
of		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
trimethoxybenzyl		I-IUPAC
)		I-IUPAC
pyrimidine		I-IUPAC
(		O
trimethoprim		O
,		O
TMP		O
)		O
with		O
the		O
potency		O
of		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
dimethoxybenzyl		I-IUPAC
)		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
piritrexim		O
,		O
PTX		O
)		O
,		O
seven		O
previously		O
undescribed		O
2,4		B-PARTIUPAC
-		I-PARTIUPAC
diamino		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
2'		I-PARTIUPAC
-		I-PARTIUPAC
methoxy		I-PARTIUPAC
-		I-PARTIUPAC
5'		I-PARTIUPAC
-		I-PARTIUPAC
(		O
substituted		B-MODIFIER
benzyl		B-PARTIUPAC
)		O
]		B-PARTIUPAC
pyrimidines		I-PARTIUPAC
were		O
synthesized		O
in		O
which		O
the		O
substituent		O
at		O
the		O
5'		O
-		O
position		O
was		O
a		O
carboxyphenyl		B-IUPAC
group		B-MODIFIER
linked		O
to		O
the		O
benzyl		B-IUPAC
moiety		B-MODIFIER
by		O
a		O
bridge		O
of		O
two		O
or		O
four		O
atoms		O
in		O
length		O
.		O
To		O
establish		O
the		O
relationship		O
between		O
the		O
physicochemical		O
and		O
biological		O
activities		O
of		O
indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
,		O
their		O
lipophilic		O
properties		O
,		O
cytotoxic		O
and		O
antimicrobial		O
activity		O
,		O
and		O
ability		O
to		O
induce		O
topoisomerase		O
II		O
dependent		O
pSP65		O
DNA		O
cleavage		O
in		O
vitro		O
were		O
investigated		O
.		O
The		O
multiple		O
-		O
alanine		O
-		O
substituted		O
peptides		O
[		O
MeTyr1		O
,		O
Ala15		O
,		O
22		O
,		O
Nle27		O
]		O
-		O
hGHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
(		O
29		O
)		O
and		O
[		O
MeTyr1		O
,		O
Ala8		O
,		O
9,15,22,28		O
,		O
Nle		O
27		O
]		O
-		O
hGHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
(		O
30		O
)		O
released		O
growth		O
hormone		O
26		O
and		O
11		O
times		O
,		O
respectively		O
,		O
more		O
effectively		O
than		O
the		O
standard		O
in		O
vitro		O
.		O
The		O
most		O
potent		O
inactivation		O
of		O
chymotrypsin		O
was		O
achieved		O
by		O
a		O
O'		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
epoxybutyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tyrosine		I-IUPAC
derivative		B-MODIFIER
.		O
The		O
thioanilide		O
side		O
chain		O
featured		O
in		O
3		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thioxoethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phthalazineacetic		I-IUPAC
acid		I-IUPAC
(		O
195		O
)		O
proved		O
to		O
be		O
an		O
effective		O
surrogate		O
for		O
benzothiazole		O
.		O
They		O
have		O
been		O
shown		O
to		O
be		O
a		O
general		O
class		O
of		O
compounds		O
which		O
exhibit		O
A1		O
adenosine		O
receptor		O
affinity		O
.		O
This		O
is		O
of		O
interest		O
with		O
regard		O
to		O
the		O
development		O
of		O
drugs		O
to		O
combat		O
resistance		O
mechanisms		O
which		O
arise		O
by		O
the		O
expression		O
of		O
the		O
topo		O
II		O
beta		O
isozyme		O
.		O
1		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
Hexadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabino		I-IUPAC
-		I-IUPAC
hexopyranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycerol		I-IUPAC
(		O
2		O
)		O
was		O
more		O
effective		O
than		O
1		O
in		O
inhibiting		O
the		O
growth		O
of		O
MCF		O
-		O
7		O
(		O
human		O
breast		O
cancer		O
)		O
and		O
its		O
adriamycin		O
-		O
resistant		O
form		O
MCF		O
-		O
7		O
/		O
adriamycin		O
,		O
and		O
murine		O
Lewis		O
lung		O
cancer		O
cells		O
.		O
The		O
following		O
properties		O
were		O
measured		O
:		O
stability		O
in		O
tissue		O
culture		O
media		O
in		O
the		O
presence		O
of		O
A549		O
lung		O
and		O
MCF		O
-		O
7		O
breast		O
tumor		O
cells		O
,		O
metabolic		O
stability		O
when		O
incubated		O
with		O
rat		O
liver		O
microsomes		O
,		O
and		O
rate		O
of		O
uptake		O
and		O
subcellular		O
location		O
in		O
A549		O
and		O
MCF		O
-		O
7		O
cells		O
.		O
The		O
present		O
studies		O
have		O
emphasized		O
that		O
the		O
presence		O
of		O
a		O
heteroatom		O
in		O
the		O
2		O
-		O
position		O
of		O
the		O
heteroaryl		O
5		O
-		O
substituent		O
greatly		O
facilitates		O
AMPA		O
receptor		O
agonist		O
activity		O
.		O
Treatment		O
of		O
6		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxypropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
m		I-IUPAC
-		I-IUPAC
methoxycinnamoylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
propa		I-IUPAC
rgylur		I-IUPAC
acil		I-IUPAC
with		O
hexamethyldisilazane		O
at		O
high		O
temperature		O
resulted		O
in		O
higher		O
yields		O
of		O
the		O
target		O
xanthine		O
than		O
the		O
standard		O
ring		O
-		O
closure		O
procedure		O
using		O
sodium		O
hydroxide		O
.		O
Base		O
-		O
catalyzed		O
ring		O
closure		O
of		O
these		O
imidazole		O
nucleosides		O
gave		O
2'		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
deazaguanosine		I-IUPAC
(		O
29		O
)		O
,		O
the		O
alpha		O
-		O
anomer		O
28		O
,		O
and		O
the		O
corresponding		O
N		O
-		O
3		O
positional		O
isomers		O
27		O
and		O
26		O
.		O
New		O
nucleoside		O
analogues		O
14-17		O
based		O
on		O
a		O
methylenecyclopropane		O
structure		O
were		O
synthesized		O
and		O
evaluated		O
for		O
antiviral		O
activity		O
.		O
However		O
,		O
for		O
all		O
compounds		O
there		O
was		O
a		O
good		O
correlation		O
(		O
R		O
&		O
gt		O
;		O
0.97		O
)		O
between		O
the		O
differential		O
uptake		O
ratio		O
(		O
DUR		O
,		O
(		O
%		O
ID		O
/		O
g		O
)		O
x		O
body		O
weight		O
(		O
g		O
)		O
/		O
100		O
)		O
in		O
individual		O
rat		O
brain		O
regions		O
at		O
30		O
min		O
after		O
injection		O
and		O
the		O
concentration		O
of		O
receptors		O
as		O
determined		O
by		O
in		O
vitro		O
quantitative		O
autoradiography		O
in		O
rat		O
.		O
Hydrophobic		O
character		O
appeared		O
to		O
influence		O
the		O
activity		O
of		O
type		O
6		O
compounds		O
.		O
The		O
most		O
active		O
compound		O
was		O
dl		B-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
benzodioxan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
]		I-IUPAC
spiro		I-IUPAC
[		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
3,1		I-IUPAC
-		I-IUPAC
benzoxazine		I-IUPAC
-		I-IUPAC
4,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
piperidin		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
9		O
)		O
,		O
and		O
various		O
modifications		O
of		O
this		O
compound		O
were		O
made		O
in		O
order		O
to		O
elucidate		O
the		O
structure		O
-		O
activity		O
relationships		O
in		O
the		O
series		O
.		O
Our		O
prior		O
publications		O
have		O
discussed		O
the		O
discovery		O
of		O
this		O
series		O
of		O
compounds		O
and		O
reported		O
some		O
preliminary		O
chemical		O
and		O
biological		O
studies		O
around		O
N		O
-		O
6		O
substitutions		O
and		O
5		O
-		O
membered		O
ring		O
variations		O
of		O
1		O
.		O
A		O
new		O
one		O
-		O
pot		O
procedure		O
is		O
described		O
for		O
the		O
preparation		O
of		O
6,19		B-IUPAC
-		I-IUPAC
epithioprogesterone		I-IUPAC
and		O
related		O
compounds		O
by		O
iodocyclization		O
of		O
a		O
19		B-IUPAC
-		I-IUPAC
sulfanylpregn		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
.		O
Structure		O
-		O
activity		O
relationships		O
are		O
discussed		O
.		O
None		O
of		O
the		O
amino		O
acids		O
4c		O
-		O
e		O
showed		O
detectable		O
affinity		O
for		O
[		O
3H		O
]		O
kainic		O
acid		O
binding		O
sites		O
.		O
In		O
contrast		O
,		O
its		O
4alpha		B-IUPAC
,		I-IUPAC
19		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
isomer		B-MODIFIER
25		O
and		O
other		O
series		O
of		O
diol		O
compounds		O
,		O
6,19		B-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
17		I-IUPAC
-		I-IUPAC
one		I-IUPAC
steroids		B-MODIFIER
,		O
were		O
moderate		O
to		O
poor		O
competitive		O
inhibitors		O
(		O
K		O
(		O
i		O
)		O
=		O
110-800		O
nM		O
)		O
.		O
Structure		O
-		O
activity		O
relationships		O
were		O
also		O
discussed		O
.		O
In		O
vitro		O
calcium		O
channel		O
antagonist		O
and		O
agonist		O
activities		O
were		O
determined		O
using		O
guinea		O
pig		O
ileum		O
longitudinal		O
smooth		O
muscle		O
(		O
GPILSM		O
)		O
and		O
guinea		O
pig		O
left		O
atrium		O
(		O
GPLA		O
)		O
assays		O
,		O
respectively		O
.		O
Condensation		O
of		O
diethyl		B-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
with		O
methyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
bromomethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrobenzoate		I-IUPAC
followed		O
by		O
catalytic		O
reduction		O
of		O
the		O
nitro		O
group		O
,		O
reductive		O
coupling		O
with		O
2		B-IUPAC
-		I-IUPAC
acetamido		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
formylpyrido		I-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
in		O
the		O
presence		O
of		O
dimethylaminoborane		O
,		O
and		O
acidolysis		O
with		O
HBr		O
/		O
AcOH		O
yielded		O
2		B-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
acetamido		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
oxopyrido		I-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methylamino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
isoindolyl		I-IUPAC
]		I-IUPAC
glutaric		I-IUPAC
acid		I-IUPAC
(		O
1		O
)		O
.		O
The		O
longer		O
analogues		O
PIP		O
(		O
5,4,5		O
)		O
and		O
PYR		O
(		O
5,4,5		O
)		O
are		O
very		O
similar		O
in		O
the		O
spacing		O
of		O
their		O
amino		O
groups		O
.		O
casei		O
.		O
Reaction		O
of		O
1		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
p		I-IUPAC
-		I-IUPAC
(		I-IUPAC
carbomethoxy		I-IUPAC
)		I-IUPAC
thiophenoxy		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butanone		I-IUPAC
(		O
10		O
)		O
with		O
hydroxylamine		O
under		O
carefully		O
controlled		O
conditions		O
gave		O
the		O
corresponding		O
oxime		O
33		O
.		O
The		O
binding		O
was		O
compared		O
with		O
that		O
of		O
PCP		O
and		O
contrasted		O
with		O
the		O
rigid		O
symmetrical		O
phencyclidine		O
derivatives		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
bicyclo		I-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexyl		I-IUPAC
]		I-IUPAC
piperidines		I-IUPAC
(		O
6		O
and		O
7		O
)		O
.		O
The		O
rates		O
of		O
hydrolysis		O
of		O
the		O
corresponding		O
triphosphates		O
by		O
recombinant		O
rat		O
NTPDase1		O
and		O
2		O
were		O
studied		O
.		O
These		O
studies		O
suggest		O
that		O
[		O
18F		O
]		O
4c		O
should		O
be		O
a		O
useful		O
compound		O
to		O
assess		O
dynamic		O
changes		O
in		O
serotonin		O
levels		O
while		O
[		O
18F		O
]		O
4d		O
,		O
with		O
its		O
high		O
contrast		O
and		O
F		O
-		O
18		O
label		O
,		O
should		O
provide		O
better		O
statistics		O
and		O
quantification		O
for		O
static		O
measurement		O
of		O
5		O
-		O
HT1A		O
receptor		O
distribution		O
.		O
Optimal		O
antitetrabenazine		O
activity		O
is		O
associated		O
with		O
the		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
phenyl		I-PARTIUPAC
series		B-MODIFIER
,		O
and		O
the		O
cis		O
secondary		O
amine		O
5a		O
is		O
approximately		O
twice		O
as		O
potent		O
as		O
the		O
cis		O
tertiary		O
amine		O
3a		O
.		O
The		O
synthesis		O
of		O
most		O
of		O
the		O
reported		O
compounds		O
was		O
achieved		O
by		O
reaction		O
of		O
2		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nonanone		I-IUPAC
with		O
the		O
suitable		O
azole		O
followed		O
by		O
reduction		O
of		O
the		O
carbonyl		B-IUPAC
group		B-MODIFIER
to		O
give		O
a		O
diastereoisomeric		O
mixture		O
of		O
N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nonyl		I-IUPAC
)		I-IUPAC
azoles		I-IUPAC
.		O
Most		O
importantly		O
,		O
it		O
was		O
found		O
that		O
irreversible		O
inactivation		O
by		O
O'		B-IUPAC
-		I-IUPAC
(		I-IUPAC
epoxyalkyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tyrosine		I-IUPAC
only		O
resulted		O
if		O
the		O
carboxy		O
terminus		O
was		O
a		O
substrate		O
(		O
i.e.		O
a		O
compound		O
with		O
free		O
carboxy		O
terminus		O
did		O
not		O
lead		O
to		O
inactivation		O
)		O
.		O
Evaluation		O
of		O
compounds		O
1		O
,		O
3-7		O
revealed		O
that		O
only		O
the		O
heterocycle		O
(		O
1		O
)		O
and		O
the		O
thiocarboxamide		O
acyclic		O
nucleoside		O
(		O
5		O
)		O
were		O
active		O
.		O
The		O
key		O
step		O
in		O
each		O
preparation		O
was		O
the		O
condensation		O
of		O
the		O
appropriate		O
chroman		B-IUPAC
-		O
,		O
thiochroman		B-IUPAC
-		I-IUPAC
,		O
or		O
benzothienyl		B-IUPAC
-		I-IUPAC
substituted		B-MODIFIER
phosphorus		B-IUPAC
ylide		I-IUPAC
,		O
obtained		O
from		O
the		O
independent		O
synthesis		O
of		O
the		O
corresponding		O
phosphonium		O
salts		O
,		O
with		O
selected		O
polyene		B-IUPAC
-		O
substituted		B-MODIFIER
aldehyde		B-IUPAC
esters		I-IUPAC
.		O
The		O
anticonvulsant		O
activity		O
of		O
these		O
compounds		O
against		O
audiogenic		O
seizures		O
was		O
evaluated		O
in		O
DBA		O
/		O
2		O
mice		O
after		O
intraperitoneal		O
(		O
ip		O
)		O
injection		O
.		O
Compounds		O
synthesized		O
in		O
this		O
study		O
inhibited		O
HIV		O
-		O
1		O
replication		O
in		O
MT		O
-		O
4		O
cells		O
in		O
the		O
submicromolar		O
to		O
namomolar		O
concentration		O
range		O
.		O
Several		O
unsymmetrical		O
guanidines		O
containing		O
a		O
naphthalene		O
ring		O
on		O
one		O
nitrogen		O
atom		O
and		O
an		O
ortho		O
-		O
or		O
a		O
meta		O
-		O
substituted		O
phenyl		O
ring		O
on		O
the		O
second		O
nitrogen		O
atom		O
,		O
e.g.		O
,		O
N		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
-		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethylphenyl		I-IUPAC
)		I-IUPAC
guanidine		I-IUPAC
(		O
36		O
)		O
,		O
showed		O
a		O
3-5		O
-		O
fold		O
increase		O
in		O
affinity		O
for		O
the		O
NMDA		O
receptor		O
ion		O
channel		O
site		O
and		O
no		O
change		O
in		O
sigma		O
receptor		O
affinity		O
compared		O
to		O
the		O
respective		O
symmetrical		O
counterparts		O
.		O
Unexpectedly		O
,		O
[		O
Ala		O
(		O
7		O
)		O
]		O
-		O
2		O
(		O
10		O
)		O
and		O
[		O
Ala		O
(		O
7		O
)		O
]		O
-		O
3		O
(		O
11		O
)		O
have		O
very		O
high		O
sst		O
(		O
4		O
)		O
affinity		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.84		O
and		O
0.98		O
nM		O
,		O
respectively		O
)		O
and		O
selectivity		O
(		O
&		O
gt		O
;		O
600		O
-		O
and		O
200		O
-		O
fold		O
,		O
respectively		O
)		O
.		O
2		B-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxypyridine		I-IUPAC
was		O
converted		O
,		O
in		O
two		O
steps		O
,		O
to		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxopyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
.		O
The		O
most		O
potent		O
type		O
6		O
inhibitor		O
was		O
alpha		B-IUPAC
,		I-IUPAC
alpha		I-IUPAC
'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
butylcarbamoyl		I-IUPAC
)		I-IUPAC
piperidino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
xylene		I-IUPAC
(		O
6i		O
)		O
.		O
The		O
novel		O
calcium		O
antagonists		O
3		B-MODIFIER
-		I-MODIFIER
N		I-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
3,4		B-IUPAC
-		I-IUPAC
dihydropyrimidines		I-IUPAC
1		O
and		O
9		O
and		O
3		B-MODIFIER
-		I-MODIFIER
N		I-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
dihydro		B-IUPAC
-		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
8		O
were		O
regioselectively		O
synthesized		O
in		O
good		O
yields		O
.		O
Initial		O
derivatives		O
of		O
these		O
series		O
(		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cyclopentylmethyl		I-IUPAC
)		I-IUPAC
carbamoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylindol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
sulfonyl		I-IUPAC
]		I-IUPAC
benzamide		I-IUPAC
(		O
5a		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cyclopentylmethyl		I-IUPAC
)		I-IUPAC
carbamoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylindol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
sulfonyl		I-IUPAC
]		I-IUPAC
benzamide		I-IUPAC
(		O
6a		O
)		O
,		O
respectively		O
)		O
,		O
when		O
compared		O
to		O
the		O
corresponding		O
indole		O
amides		O
(		O
e.g.		O
28		O
and		O
29		O
)		O
,		O
were		O
found		O
to		O
be		O
approximately		O
10		O
-		O
fold		O
less		O
potent		O
in		O
vitro		O
and		O
substantially		O
less		O
active		O
when		O
administered		O
orally		O
to		O
guinea		O
pigs		O
.		O
Attaching		O
the		O
ligand		O
to		O
a		O
polyamine		O
vector		O
had		O
a		O
profound		O
effect		O
on		O
increasing		O
the		O
iron		O
-		O
clearing		O
efficiency		O
of		O
this		O
chelator		O
relative		O
to		O
its		O
parent		O
drug		O
.		O
The		O
syntheses		O
and		O
antinociceptive		O
effects		O
of		O
these		O
analogues		O
of		O
general		O
formula		O
H		O
-		O
Lys		O
-		O
Trp		O
(		O
R		O
)		O
-		O
OMe		O
[		O
R		O
=		O
phenylsulfenyl		B-IUPAC
(		O
PS		O
)		O
(		O
9		O
)		O
;		O
R		O
=		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
carbomethyoxyphenyl		I-IUPAC
)		I-IUPAC
sulfenyl		I-IUPAC
(		O
CmPS		O
)		O
(		O
10		O
)		O
;		O
R		O
=		O
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
sulfenyl		I-IUPAC
(		O
pNPS		O
)		O
(		O
11		O
)		O
;		O
R		O
=		O
(		B-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dinitrophenyl		I-IUPAC
)		I-IUPAC
sulfenyl		I-IUPAC
(		O
DNPS		O
)		O
(		O
12		O
)		O
;		O
R		O
=		O
[		B-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
acetylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbomethoxyethyl		I-IUPAC
]		I-IUPAC
sulfenyl		I-IUPAC
(		O
AacCmES		O
)		O
(		O
13		O
)		O
;		O
R		O
=		O
[		B-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
acetylamino		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
sulfenyl		I-IUPAC
(		O
AacPS		O
)		O
(		O
17		O
)		O
;		O
R		O
=		O
tert		B-IUPAC
-		I-IUPAC
butylsulfenyl		I-IUPAC
(		O
t		O
-		O
BuS		O
)		O
(		O
23		O
)		O
;		O
R		O
=		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
carbomethoxyethyl		I-IUPAC
)		I-IUPAC
sulfenyl		I-IUPAC
(		O
CmES		O
)		O
(		O
24		O
)		O
]		O
are		O
described		O
.		O
The		O
most		O
striking		O
divergence		O
of		O
this		O
correlation		O
was		O
the		O
high		O
potency		O
combined		O
with		O
a		O
high		O
stability		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
acetylamino		I-IUPAC
-		O
substituted		B-MODIFIER
derivative		I-MODIFIER
11e		O
.		O
The		O
release		O
of		O
5		O
from		O
6		O
following		O
metabolism		O
was		O
confirmed		O
and		O
shown		O
by		O
use		O
of		O
the		O
bioassay		O
system		O
to		O
be		O
an		O
event		O
of		O
similar		O
toxicity		O
to		O
release		O
of		O
4		O
from		O
18		O
;		O
in		O
vivo		O
,		O
however		O
,		O
6		O
(		O
LD50		O
330		O
mg		O
/		O
kg		O
)		O
was		O
more		O
toxic		O
to		O
mice		O
than		O
18		O
(		O
LD50		O
greater		O
than		O
500		O
mg		O
/		O
kg		O
)		O
.		O
The		O
utility		O
of		O
polyamines		O
as		O
vectors		O
for		O
the		O
intracellular		O
transport		O
of		O
iron		O
chelators		O
is		O
further		O
described		O
.		O
One		O
compound		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
10,11		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenz		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
f		I-IUPAC
]		I-IUPAC
azepin		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
piperidinecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
23		O
)		O
,		O
was		O
selected		O
for		O
further		O
biological		O
investigations		O
and		O
showed		O
a		O
protective		O
index		O
comparable		O
to		O
or		O
slightly		O
better		O
than		O
that		O
of		O
the		O
recently		O
launched		O
anticonvulsant		O
product		O
5		O
(		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
butenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
piperidinecarboxylic		I-IUPAC
acid		I-IUPAC
)		O
.		O
A		O
novel		O
series		O
of		O
nonpeptide		O
CCK		O
(		O
2		O
)		O
receptor		O
antagonists		O
has		O
been		O
prepared		O
,		O
in		O
which		O
2,7		B-IUPAC
-		I-IUPAC
dioxo		I-IUPAC
-		I-IUPAC
2,3,4,5,6,7		I-IUPAC
-		I-IUPAC
hexahydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
h		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1		I-IUPAC
,		I-IUPAC
4		I-IUPAC
]		I-IUPAC
diazonine		I-IUPAC
(		O
5		O
)		O
was		O
used		O
as		O
a		O
chemical		O
template		O
.		O
In		O
the		O
adenylate		O
cyclase		O
assay		O
,		O
the		O
compounds		O
behave		O
as		O
potent		O
D		O
-		O
2		O
agonists		O
.		O
The		O
high		O
potency		O
of		O
several		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alkoxy		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alkylthio		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
sulfamoylbenzoic		I-IUPAC
acids		I-IUPAC
confirmed		O
previous		O
suggestions		O
that		O
the		O
apparent		O
diuretic		O
effect		O
of		O
4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
alkylamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisothiazole		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
originates		O
from		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
sulfamoylbenzoic		I-IUPAC
acid		I-IUPAC
derivatives		B-MODIFIER
due		O
to		O
an		O
existing		O
equilibrium		O
in		O
plasma		O
.		O
In		O
fact		O
,		O
[		O
Tyr		O
(		O
7		O
)		O
]		O
-		O
2		O
(		O
6		O
)		O
and		O
[		O
Tyr		O
(		O
7		O
)		O
]		O
-		O
3		O
(		O
7		O
)		O
show		O
ca.		O
5		O
-		O
fold		O
selectivity		O
for		O
sst		O
(		O
4		O
)		O
,		O
and		O
[		O
Aph		O
(		O
7		O
)		O
]		O
-		O
2		O
(		O
8		O
)		O
and		O
[		O
Aph		O
(		O
7		O
)		O
]		O
-		O
3		O
(		O
9		O
)		O
have		O
high		O
sst		O
(		O
4		O
)		O
affinity		O
(		O
IC		O
(		O
50		O
)		O
=		O
1.2		O
and		O
0.88		O
nM		O
,		O
respectively		O
)		O
and		O
selectivity		O
,		O
suggesting		O
that		O
indeed		O
an		O
l		O
-		O
residue		O
at		O
position		O
8		O
will		O
direct		O
selectivity		O
toward		O
sst		O
(		O
4		O
)		O
.		O
Alkylation		O
of		O
7		O
by		O
13a		O
,		O
b		O
led		O
to		O
10		B-IUPAC
-		I-IUPAC
propargyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
(		O
5		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
propargyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
(		O
6		O
)		O
.		O
The		O
syntheses		O
of		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
4RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxypiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
4		O
)		O
,		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
5SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxypiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
20		O
)		O
,		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
4SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
acetamidopiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
10		O
)		O
,		O
and		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
5SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
acetamidopiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
18		O
)		O
,		O
related		O
to		O
the		O
specific		O
gamma		B-IUPAC
-		I-IUPAC
aminobutyric		I-IUPAC
acid		I-IUPAC
(		O
GABA		O
)		O
uptake		O
inhibitors		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
piperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
nipecotic		O
acid		O
)		O
and		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
4SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxypiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
21		O
)		O
,		O
are		O
described		O
.		O
The		O
absolute		O
stereochemical		O
requirements		O
for		O
binding		O
were		O
found		O
to		O
be		O
2S		O
,		O
4R		O
,		O
showing		O
that		O
,		O
in		O
common		O
with		O
other		O
glycine		O
-		O
site		O
NMDA		O
receptor		O
ligands		O
,		O
the		O
unnatural		O
configuration		O
at		O
the		O
alpha		O
-		O
amino		O
acid		O
center		O
is		O
required		O
.		O
carinii		O
)		O
and		O
IC50		O
(		O
rat		O
)		O
/		O
IC50		O
(		O
T		O
.		O
A		O
diverse		O
range		O
of		O
chromen		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
,		O
chromen		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
pyrimidoisoquinolin		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
derivatives		B-MODIFIER
was		O
synthesized		O
and		O
evaluated		O
for		O
inhibitory		O
activity		O
against		O
the		O
DNA		O
repair		O
enzyme		O
DNA		O
-		O
dependent		O
protein		O
kinase		O
(		O
DNA		O
-		O
PK		O
)		O
,		O
with		O
a		O
view		O
to		O
elucidating		O
structure		O
-		O
activity		O
relationships		O
for		O
potency		O
and		O
kinase		O
selectivity		O
.		O
The		O
most		O
potent		O
alpha2		O
-		O
agonist		O
was		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yloxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazole		I-IUPAC
(		O
7		O
)		O
,		O
whose		O
key		O
pharmacophoric		O
features		O
closely		O
matched		O
those		O
found		O
in		O
the		O
alpha2		O
-		O
agonist		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
exo		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenylprop		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
exo		I-IUPAC
-		I-IUPAC
norbornyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxazoline		I-IUPAC
(		O
15		O
)		O
.		O
The		O
optimal		O
compound		O
19		O
UR		O
-		O
12670		O
)		O
,		O
bearing		O
the		O
3,3		B-IUPAC
-		I-IUPAC
diphenylpropanoyl		I-IUPAC
moiety		B-MODIFIER
,		O
exhibited		O
very		O
high		O
in		O
vitro		O
and		O
in		O
vivo		O
potency		O
IC50		O
=		O
0.0076		O
microM		O
for		O
the		O
in		O
vitro		O
PAF		O
-		O
induced		O
platelet		O
aggregation		O
assay		O
,		O
ID50		O
=		O
0.0086		O
mg		O
/		O
kg		O
for		O
the		O
in		O
vivo		O
PAF		O
-		O
induced		O
hypotension		O
test		O
in		O
normotensive		O
rats		O
,		O
and		O
ID50		O
=		O
0.092		O
mg		O
/		O
kg		O
po		O
and		O
0.0008		O
mg		O
/		O
kg		O
i		O
.		O
Equally		O
effective		O
was		O
an		O
[		O
i		O
-		O
(		O
i		O
+		O
3		O
)		O
]		O
constraint		O
yielding		O
the		O
18		O
-		O
membered		O
ring		O
cyclo		O
(		O
25-28		O
)		O
[		O
MeTyr1		O
,		O
Ala15		O
,		O
Glu25		O
,		O
Nle		O
,		O
27Lys28		O
]		O
-		O
hGHRH		O
-		O
(		O
1-29		O
)		O
-		O
NH2		O
(		O
51		O
)		O
which		O
was		O
14		O
times		O
more		O
potent		O
than		O
the		O
standard		O
.		O
Rat		O
brain		O
monoamine		O
levels		O
were		O
unaltered		O
1		O
week		O
following		O
a		O
single		O
high		O
dose		O
(		O
10		O
or		O
20		O
mg		O
/		O
kg		O
,		O
sc		O
)		O
of		O
6		O
or		O
11		O
,		O
or		O
two		O
weeks		O
following		O
a		O
subacute		O
dosing		O
regimen		O
(		O
20		O
mg		O
/		O
kg		O
,		O
sc		O
,		O
twice		O
a		O
day		O
for		O
4		O
days		O
)		O
.		O
The		O
6		B-IUPAC
-		I-IUPAC
thienylimidazo		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiazoles		I-IUPAC
were		O
more		O
potent		O
in		O
mammalian		O
than		O
in		O
nematode		O
mitochondria		O
and		O
had		O
an		O
average		O
titer		O
of		O
0.11		O
mM		O
for		O
2		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiazole		I-IUPAC
(		O
10		O
)		O
.		O
The		O
aim		O
of		O
the		O
current		O
study		O
concerns		O
the		O
synthesis		O
of		O
amantidine		O
analogues		O
by		O
appending		O
primary		O
amines		O
to		O
1		B-IUPAC
-		I-IUPAC
boraadamantane		I-IUPAC
to		O
evaluate		O
such		O
compounds		O
for		O
CD81		O
-		O
dependent		O
antiproliferation		O
of		O
CD81		O
-		O
enriched		O
cell		O
lines		O
(		O
astrocyte		O
)		O
vs		O
CD81		O
-		O
deficient		O
cell		O
lines		O
(		O
C6		O
glioma		O
)		O
.		O
Structure		O
proof		O
of		O
target		O
nucleosides		O
was		O
provided		O
by		O
independent		O
synthesis		O
,		O
1H		O
NMR		O
,		O
and		O
UV		O
.		O
Contrary		O
to		O
the		O
literature		O
reports		O
,		O
no		O
enhancement		O
in		O
activity		O
due		O
to		O
the		O
presence		O
of		O
a		O
hydroxy		O
group		O
was		O
found		O
when		O
the		O
cytotoxicity		O
of		O
furanones		O
13a		O
,		O
b		O
,		O
d		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1'		I-IUPAC
-		I-IUPAC
hydroxyalkyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylenedihydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
6a		O
,		O
b		O
,		O
d		O
was		O
compared		O
.		O
In		O
the		O
6		B-IUPAC
-		I-IUPAC
hydroxydopamine		I-IUPAC
-		O
lesioned		O
rat		O
model		O
,		O
this		O
compound		O
was		O
also		O
quite		O
effective		O
,		O
with		O
a		O
minimum		O
effective		O
dose		O
of		O
3		O
mg		O
/		O
kg		O
po		O
.		O
Their		O
affinity		O
to		O
beta		O
1		O
-		O
and		O
beta		O
-		O
2		O
-		O
adrenoceptors		O
was		O
determined		O
and		O
compared		O
with		O
the		O
affinity		O
of		O
known		O
beta		O
-		O
blockers		O
.		O
With		O
an		O
in		O
vitro		O
pA2		O
(		O
in		O
the		O
absence		O
of		O
Mg2+		O
)		O
=		O
9.12		O
+		O
/		O
-		O
0.09		O
,		O
dP		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
]		O
AVT		O
is		O
(		O
7		O
)		O
one		O
of		O
the		O
most		O
potent		O
in		O
vitro		O
oxytocin		O
antagonists		O
reported		O
to		O
date		O
.		O
5		O
-		O
Bromo		O
-		O
dUMP		O
and		O
5		O
-		O
iodo		O
-		O
dUMP		O
showed		O
substrate		O
activity		O
independent		O
of		O
N		B-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
,		I-IUPAC
N		I-IUPAC
(		I-IUPAC
10		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methylenetetrahydrofolate		I-IUPAC
in		O
the		O
thymidylate		O
synthase		O
-		O
catalyzed		O
dehalogenation		O
reaction		O
.		O
3,6		B-IUPAC
-		I-IUPAC
Dichloro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
isopropyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
methylflavone		I-IUPAC
,		O
11e		O
,		O
was		O
both		O
potent		O
and		O
highly		O
selective		O
(		O
approximately		O
200		O
-		O
fold		O
)		O
for		O
human		O
A3		O
receptors		O
(		O
Ki		O
=		O
0.56		O
microM		O
)		O
.		O
Incorporation		O
of		O
substituted		B-MODIFIER
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
benzylidene		I-IUPAC
moieties		B-MODIFIER
onto		O
the		O
7		O
-		O
keto		O
precursor		O
of		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
morphan		I-IUPAC
,		O
(		O
+		O
)		O
-		O
1		O
,		O
produces		O
compounds		O
(		O
-		O
)		O
-		O
2		O
through		O
(		O
-		O
)		O
-		O
7		O
(		O
5.8-32.0		O
nM		O
,		O
sigma		O
1		O
)		O
,		O
which		O
have		O
between		O
a		O
25		O
-		O
and		O
131		O
-		O
fold		O
increase		O
in		O
affinity		O
for		O
the		O
sigma		O
1		O
receptor		O
subtype		O
relative		O
to		O
the		O
keto		O
precursor		O
(		O
+		O
)		O
-		O
1		O
(		O
Ki		O
=		O
762		O
nM		O
,		O
sigma		O
1		O
)		O
.		O
In		O
the		O
series		O
of		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
thienylvinyl		I-IUPAC
)		I-IUPAC
imidazothiazoles		I-IUPAC
,		O
the		O
hydrobromide		B-MODIFIER
of		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thienylvinyl		I-IUPAC
)		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiazole		I-IUPAC
(		O
E		O
-		O
5		O
.		O
Competition		O
binding		O
in		O
cells		O
stably		O
expressing		O
the		O
transfected		O
human		O
SERT		O
,		O
dopamine		O
transporter		O
(		O
DAT		O
)		O
,		O
and		O
norepinephrine		O
transporter		O
(		O
NET		O
)		O
using		O
[		O
(		O
3		O
)		O
H		O
]		O
citalopram		O
,		O
[		O
(		O
3		O
)		O
H		O
]		O
WIN		O
35,428		O
,		O
and		O
[		O
(		O
3		O
)		O
H		O
]		O
nisoxetine		O
,		O
respectively		O
,		O
demonstrated		O
the		O
following		O
order		O
of		O
SERT		O
affinity		O
(		O
K		O
(		O
i		O
)		O
in		O
nM		O
)		O
:		O
ZIENT		O
(		O
0.05		O
)		O
&		O
gt		O
;		O
nor		O
-		O
CIT		O
(		O
0.12		O
)		O
&		O
gt		O
;		O
&		O
gt		O
;		O
EIENT		O
(		O
1.15		O
)		O
&		O
gt		O
;		O
fluvoxamine		O
(		O
1.46		O
)		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azidovinyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
derivatives		B-MODIFIER
9a		O
-		O
c		O
were		O
found		O
to		O
exhibit		O
potent		O
and		O
selective		O
in		O
vitro		O
anti		O
-		O
HBV		O
activity		O
against		O
duck		O
hepatitis		O
B		O
virus		O
(		O
DHBV		O
)		O
infected		O
primary		O
duck		O
hepatocytes		O
at		O
low		O
concentrations		O
(		O
EC		O
(		O
50		O
)		O
=		O
0.01-0.1		O
microg		O
/		O
mL		O
range		O
)		O
.		O
Attachment		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
sulfonyl		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
thiazolidinedione		I-IUPAC
moiety		B-MODIFIER
to		O
the		O
2		O
-		O
naphthalene		O
position		O
led		O
to		O
optimum		O
activity		O
.		O
The		O
most		O
selective		O
A		O
(		O
3		O
)		O
AR		O
antagonist		O
(		O
&		O
gt		O
;		O
200		O
-		O
fold		O
)		O
was		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
phenyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyclohexyladenine		I-IUPAC
(		O
22		O
)		O
.		O
Med.		O
Chem.		O
1993		O
,		O
36		O
,		O
801-810		O
)		O
.		O
Potencies		O
at		O
central		O
pre		O
-		O
(		O
auto		O
-		O
)		O
and		O
postsynaptic		O
DA		O
receptors		O
were		O
determined		O
by		O
a		O
biochemical		O
and		O
a		O
behavioral		O
method		O
,		O
respectively		O
.		O
The		O
2		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
residue		B-MODIFIER
in		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylbenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylpyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
(		O
ADPEP		O
,		O
1		O
)		O
and		O
in		O
the		O
corresponding		O
pyrimido		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
(		O
APEPI		O
,		O
3		O
)		O
could		O
be		O
bioisosterically		O
replaced		O
by		O
heterocyclic		O
rings		O
,		O
such		O
as		O
2		B-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
.		O
Preliminary		O
findings		O
on		O
the		O
acute		O
toxicity		O
of		O
the		O
poly		O
(		O
HOPO		O
)		O
ligands		O
and		O
HOPO		O
monomers		O
are		O
presented		O
in		O
an		O
appendix		O
.		O
The		O
triethyl		O
and		O
tripropyl		O
ether		O
derivatives		O
of		O
the		O
flavonol		O
galangin		O
,		O
4		O
,		O
had		O
Ki		O
values		O
of		O
0.3		O
-		O
0.4		O
microM		O
at		O
human		O
A3		O
receptors		O
.		O
For		O
each		O
compound		O
,		O
the		O
corresponding		O
carboxylic		O
acid		O
was		O
identified		O
as		O
a		O
major		O
metabolite		O
in		O
blood		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
The		O
synthesis		O
and		O
sigma		O
receptor		O
affinity		O
of		O
a		O
series		O
of		O
conformationally		O
restricted		O
derivatives		O
of		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylethylenedi		I-IUPAC
amine		I-IUPAC
(		O
1		O
)		O
is		O
described		O
.		O
On		O
the		O
other		O
hand		O
,		O
(		O
R		O
)		O
-		O
APPA		O
(		O
3		O
)		O
and		O
(		O
R		O
)		O
-		O
2		O
-		O
Py		O
-		O
AMPA		O
(		O
6		O
)		O
have		O
been		O
shown		O
to		O
be		O
weak		O
AMPA		O
antagonists		O
.		O
The		O
combination		O
of		O
the		O
2,2,4,4		B-IUPAC
-		I-IUPAC
tetramethylthiochroman		I-IUPAC
group		B-MODIFIER
and		O
the		O
benzoic		O
acid		O
(		O
or		O
ester		O
)		O
terminal		O
group		O
seemed		O
to		O
enhance		O
the		O
biological		O
action		O
which		O
resembles		O
that		O
found		O
with		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5,6,7,8		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
5,5,8,8		I-IUPAC
-		I-IUPAC
tetramethyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthalenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
TTNPB		O
,		O
6b		O
)		O
,		O
a		O
well		O
-		O
known		O
model		O
system		O
.		O
The		O
intravenous		O
administration		O
of		O
3h		O
significantly		O
reduced		O
the		O
urinary		O
bladder		O
pressure		O
in		O
anesthetized		O
male		O
rats		O
(		O
ED		O
(		O
50		O
)		O
=		O
48		O
microg		O
/		O
kg		O
)		O
without		O
cardiovascular		O
side		O
effects		O
.		O
Both		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
,		O
Tyr		O
(		O
11		O
)		O
]		O
-		O
Cbm		O
-		O
SRIF		O
(		O
27		O
)		O
and		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DCys		O
(		O
3		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
,		O
Tyr		O
(		O
11		O
)		O
]		O
-		O
Cbm		O
-		O
SRIF		O
(		O
29		O
)		O
show		O
agonistic		O
activity		O
in		O
a		O
cAMP		O
assay		O
;		O
therefore		O
,		O
the		O
structural		O
basis		O
for		O
the		O
agonist		O
property		O
of		O
this		O
family		O
of		O
analogues		O
is		O
not		O
contingent		O
upon		O
the		O
chirality		O
of		O
the		O
Cys		O
residue		O
at		O
position		O
3		O
as		O
shown		O
to		O
be		O
the		O
case		O
in		O
18		O
-		O
membered		O
ring		O
SRIF		O
octapeptides		O
.		O
The		O
same		O
sequence		O
of		O
reactions		O
starting		O
with		O
N6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
omega		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
derivatives		B-MODIFIER
of		O
N6		O
-		O
CH3		O
-		O
AMP		O
gave		O
N6		O
-		O
CH3		O
,		O
N6		O
-		O
(		O
CH2		O
)		O
nH		O
(		O
CH3		O
)		O
CO		O
(		O
CH2		O
)		O
mNHCOCH2I		O
derivatives		O
of		O
ATP		O
(		O
n		O
=		O
4		O
,		O
m		O
=		O
3		O
,		O
5		O
or		O
6		O
;		O
n		O
=		O
6		O
,		O
m		O
=		O
5		O
or		O
6		O
)		O
.		O
The		O
inhibitory		O
action		O
of		O
E		O
-		O
5		O
.		O
A		O
convenient		O
synthesis		O
of		O
8		O
-		O
azapurine		O
ribonucleosides		O
substituted		O
at		O
the		O
6		O
position		O
with		O
thio		B-IUPAC
,		O
alkylthio		B-IUPAC
,		O
alkoxy		B-IUPAC
,		O
amino		B-IUPAC
,		O
and		O
alkylamino		B-IUPAC
groups		B-MODIFIER
is		O
described		O
.		O
Since		O
hypoxic		O
cells		O
remote		O
from		O
the		O
tumor		O
blood		O
supply		O
may		O
have		O
a		O
greater		O
capacity		O
for		O
reductive		O
reactions		O
than		O
well		O
-		O
oxygenated		O
cells		O
,		O
we		O
have		O
prepared		O
a		O
series		O
of		O
anthraquinone		O
prodrugs		O
which		O
may		O
be		O
capable		O
of		O
generating		O
a		O
reactive		O
quinonemethide		O
species		O
following		O
enzymatic		O
reduction		O
to		O
the		O
hydroquinone		O
and		O
loss		O
of		O
the		O
substituent		O
on		O
the		O
methylene		O
group		O
in		O
the		O
2		O
position		O
.		O
Seven		O
compounds		O
strongly		O
inhibited		O
tubulin		O
polymerization		O
with		O
activities		O
higher		O
or		O
comparable		O
to		O
those		O
of		O
the		O
reference		O
compounds		O
such		O
as		O
colchicine		O
,		O
podophyllotoxin		O
,		O
and		O
nocodazole		O
.		O
An		O
increase		O
in		O
the		O
size		O
of		O
the		O
4		O
substitutent		O
of		O
the		O
3		O
-		O
(		O
aryloxy		O
)		O
moiety		O
to		O
caproamido		O
leads		O
to		O
a		O
substantially		O
higher		O
affinity		O
for		O
the		O
beta		O
1		O
-		O
-		O
adrenoceptor		O
of		O
rat		O
ventricular		O
muscle		O
in		O
the		O
presence		O
of		O
the		O
3,4		B-IUPAC
-		I-IUPAC
dimethoxyphenethyl		I-IUPAC
than		O
in		O
the		O
presence		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
hydroxyphenethyl		I-IUPAC
or		O
isopropyl		O
group		O
;		O
this		O
combination		O
also		O
gave		O
the		O
highest		O
cardioselectivity		O
.		O
In		O
particular		O
,		O
compounds		O
37		O
and		O
47		O
proved		O
lethal		O
at		O
100		O
micrograms		O
/		O
mL		O
after		O
an		O
exposure		O
of		O
only		O
1		O
h		O
.		O
Analogs		O
with		O
dihydroxy		B-IUPAC
substituents		B-MODIFIER
(		O
catechols		O
)		O
,		O
as		O
well		O
as		O
nitrogen		O
substituents		O
larger		O
than		O
methyl		O
,		O
had		O
little		O
affinity		O
for		O
[		O
3H		O
]		O
4		O
binding		O
sites		O
and		O
did		O
not		O
significantly		O
affect		O
TH		O
activity		O
.		O
Several		O
compounds		O
demonstrated		O
moderate		O
to		O
high		O
affinity		O
for		O
the		O
5		O
-		O
HT1A		O
receptor		O
binding		O
site		O
,		O
with		O
compounds		O
37		O
and		O
38		O
containing		O
2		B-IUPAC
-		I-IUPAC
pyrimidinylpiperazinyl		I-IUPAC
and		O
[		B-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
piperazinyl		I-IUPAC
moieties		B-MODIFIER
and		O
compound		O
47		O
containing		O
the		O
2		B-IUPAC
-		I-IUPAC
pyrazinylpiperazinyl		I-IUPAC
moiety		B-MODIFIER
displaying		O
the		O
highest		O
affinity		O
(		O
Ki		O
values		O
of		O
10		O
,		O
4		O
,		O
and		O
9		O
nM		O
,		O
respectively		O
)		O
.		O
brucei		O
parasite		O
growth		O
in		O
vitro		O
at		O
&		O
lt		O
;		O
1		O
microM		O
.		O
Compounds		O
14		O
+		O
16		O
were		O
converted		O
to		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
methylene		I-IUPAC
derivatives		B-MODIFIER
28		O
and		O
29		O
which		O
were		O
separated		O
and		O
deprotected		O
to		O
give		O
14		O
and		O
16		O
.		O
Introduction		O
of		O
a		O
4		B-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
substituent		B-MODIFIER
at		O
the		O
indole		O
nitrogen		O
atom		O
rendered		O
very		O
selective		O
sigma		O
2		O
ligands		O
with		O
subnanomolar		O
affinity		O
for		O
the		O
sigma		O
2		O
binding		O
site		O
.		O
Their		O
protected		O
precursors		O
were		O
synthesized		O
either		O
entirely		O
by		O
the		O
solid		O
-		O
phase		O
method		O
or		O
by		O
a		O
combination		O
of		O
solid		O
-		O
phase		O
and		O
solution		O
methods		O
(		O
1		O
+		O
8		O
or		O
8		O
+		O
1		O
couplings		O
)		O
.		O
The		O
compounds		O
were		O
prepared		O
by		O
nucleophilic		O
displacement		O
of		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
chloromethyl		I-IUPAC
)		I-IUPAC
furo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
2		O
)		O
with		O
the		O
appropriate		O
thiol		O
,		O
amine		O
,		O
or		O
naphthol		O
.		O
The		O
low		O
adrenomedullary		O
affinity		O
observed		O
with		O
[		B-IUPAC
14C		I-IUPAC
]		I-IUPAC
guanidine		I-IUPAC
and		O
m		B-IUPAC
-		I-IUPAC
[		I-IUPAC
125I		I-IUPAC
]		I-IUPAC
iodobenzylamine		I-IUPAC
demonstrates		O
the		O
uniqueness		O
of		O
the		O
aralkylguanidine		O
structure		O
.		O
In		O
addition		O
5a		O
exhibited		O
no		O
effect		O
on		O
the		O
contraction		O
induced		O
by		O
histamine		O
or		O
acetylcholine		O
.		O
The		O
higher		O
[		O
ST		O
-		O
CB		O
]		O
/		O
CB		O
ratio		O
observed		O
for		O
2B		O
was		O
corroborated		O
by		O
the		O
results		O
of		O
an		O
in		O
vitro		O
binding		O
assay		O
.		O
A		O
series		O
of		O
four		O
halogenated		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
analogues		B-MODIFIER
of		O
L		B-IUPAC
-		I-IUPAC
fucose		I-IUPAC
(		O
4		O
,		O
X		O
=		O
F		O
,		O
Cl		O
,		O
Br		O
,		O
and		O
I		O
)		O
have		O
been		O
obtained		O
starting		O
from		O
1,2		B-IUPAC
:		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
isopropylidene		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
galactose		I-IUPAC
.		O
These		O
results		O
suggest		O
that		O
the		O
hydroxyl		O
group		O
of		O
7		O
functions		O
as		O
an		O
H		O
-		O
bond		O
acceptor		O
,		O
rather		O
than		O
a		O
donor		O
,		O
and		O
that		O
on		O
interaction		O
of		O
7		O
,		O
and		O
the		O
pyrido		O
analogues		O
9		O
,		O
with		O
a		O
common		O
receptor		O
,		O
an		O
orbital		O
occupied		O
by		O
one		O
of		O
the		O
oxygen		O
lone		O
pair		O
electrons		O
of		O
7		O
must		O
assume		O
the		O
same		O
orientation		O
as		O
the		O
orbital		O
occupied		O
by		O
the		O
pyridine		O
nitrogen		O
lone		O
pair		O
.		O
The		O
gamma		B-PARTIUPAC
-		I-PARTIUPAC
methylene		I-PARTIUPAC
derivatives		B-MODIFIER
of		O
MTX		O
and		O
AMT		O
are		O
attractive		O
because		O
of		O
their		O
potential		O
to		O
act		O
as		O
Michael		O
acceptors		O
within		O
the		O
DHFR		O
active		O
site		O
.		O
In		O
a		O
preliminary		O
study		O
,		O
a		O
series		O
of		O
N		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
14		I-PARTIUPAC
)		I-PARTIUPAC
C		I-PARTIUPAC
]		I-PARTIUPAC
ethylpiperidin		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
yl		I-PARTIUPAC
or		O
-		B-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
ylmethanol		I-PARTIUPAC
esters		I-PARTIUPAC
(		O
acetyl		O
and		O
propionyl		O
esters		O
)		O
were		O
newly		O
designed		O
and		O
evaluated		O
in		O
vitro		O
regarding		O
the		O
reactivity		O
with		O
and		O
specificity		O
to		O
AChE		O
using		O
purified		O
human		O
enzymes		O
,		O
leading		O
to		O
a		O
novel		O
(		O
18		O
)		O
F		O
-		O
labeled		O
acetylcholine		O
analogue		O
,		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
18		I-IUPAC
)		I-IUPAC
F		I-IUPAC
]		I-IUPAC
fluoroethylpiperidin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
acetate		I-IUPAC
.		O
They		O
displayed		O
high		O
potency		O
on		O
all		O
the		O
assays		O
and		O
some		O
selectivity		O
for		O
alpha1a		O
and		O
alpha1d		O
subtypes		O
.		O
The		O
present		O
work		O
explored		O
3		B-IUPAC
-		I-IUPAC
alkylamino		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
benzothiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
diversely		O
substituted		O
in		O
the		O
7		O
-		O
position		O
.		O
A		O
5		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
phenylacetyl		I-IUPAC
derivative		B-MODIFIER
,		O
12		O
,		O
was		O
470		O
-		O
fold		O
selective		O
for		O
human		O
A3		O
vs		O
rat		O
A1		O
receptors		O
with		O
a		O
Ki		O
value		O
of		O
0.65		O
nM		O
.		O
Biological		O
evaluation		O
in		O
Limulus		O
photoreceptors		O
showed		O
that		O
1L		B-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
1,3,4		I-IUPAC
-		I-IUPAC
trisphosphate		I-IUPAC
was		O
much		O
more		O
active		O
than		O
the		O
D		O
-		O
enantiomer		O
,		O
producing		O
repetitive		O
bursts		O
of		O
depolarization		O
due		O
to		O
mobilization		O
of		O
intracellular		O
calcium		O
.		O
In		O
conclusion		O
,		O
small		O
cyclic		O
peptides		O
were		O
created		O
,		O
which		O
mimic		O
the		O
structure		O
and		O
activity		O
of		O
the		O
binding		O
epitope		O
of		O
uPA		O
to		O
uPAR		O
and		O
which		O
may		O
serve		O
as		O
novel		O
therapeutic		O
agents		O
in		O
cancer		O
metastasis		O
.		O
The		O
syntheses		O
of		O
the		O
fixed		O
Northern		O
conformers		O
1-5		O
were		O
performed		O
by		O
Mitsunobu		O
coupling		O
of		O
the		O
heterocyclic		O
bases		O
with		O
the		O
chiral		O
carbocyclic		O
alcohol		O
6		O
[		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2S		I-IUPAC
,		I-IUPAC
4R		I-IUPAC
,		I-IUPAC
5S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydrox		I-IUPAC
ybicyclo		I-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexane		I-IUPAC
]		O
,		O
while		O
the		O
synthesis		O
of		O
the		O
Southern		O
conformer		O
,		O
(		O
S		O
)		O
-		O
methanocarba		O
-		O
T		O
(		O
12		O
)		O
,		O
was		O
reported		O
earlier		O
.		O
Previously		O
we		O
have		O
reported		O
the		O
discovery		O
of		O
ABT		O
-		O
627		O
(		O
1		O
,		O
A		O
-		O
147627		O
,		O
active		O
enantiomer		O
of		O
A		O
-		O
127722		O
)		O
,		O
a		O
2,4		B-IUPAC
-		I-IUPAC
diaryl		I-IUPAC
substituted		B-MODIFIER
pyrrolidine		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
based		O
endothelin		O
receptor		O
-		O
A		O
antagonist		O
.		O
Of		O
particular		O
interest		O
are		O
1,3		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
methoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,5		I-IUPAC
-		I-IUPAC
diphenylhydantoin		I-IUPAC
and		O
3		B-IUPAC
-		I-IUPAC
acetoxymethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenylhydantoin		I-IUPAC
,		O
which		O
show		O
good		O
activity		O
against		O
maximal		O
electroshock		O
seizures		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
methoxymethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenylhydantoin		I-IUPAC
,		O
which		O
is		O
effective		O
against		O
both		O
maximal		O
electroshock		O
and		O
pentylenetetrazole		B-IUPAC
.		O
Herein		O
we		O
report		O
the		O
effects		O
of		O
varying		O
stereochemistry		O
around		O
the		O
hydroisoquinoline		O
ring		O
;		O
of		O
tetrahydro		O
-		O
versus		O
decahydroisoquinoline		O
;		O
of		O
having		O
the		O
carboxylic		O
acid		O
at		O
C		O
-		O
1		O
versus		O
C		O
-		O
3		O
;		O
of		O
varying		O
the		O
length		O
of		O
the		O
carbon		O
chain		O
connecting		O
a		O
tetrazole		O
to		O
the		O
bicyclic		O
nucleus		O
;		O
and		O
of		O
holding		O
the		O
connecting		O
chain		O
constant		O
at		O
two		O
atoms		O
,		O
the		O
effect		O
of		O
heteroatom		O
substitution		O
in		O
the		O
position		O
adjacent		O
to		O
the		O
bicyclic		O
nucleus		O
and		O
substitution		O
with		O
methyl		O
or		O
phenyl		O
on		O
the		O
chain		O
.		O
(		B-IUPAC
6R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
Deazatetrahydrofolate		I-IUPAC
,		O
in		O
which		O
the		O
side		O
chain		O
is		O
free		O
to		O
rotate		O
,		O
was		O
rapidly		O
converted		O
to		O
long		O
-		O
chain		O
polyglutamates		O
.		O
A		O
trace		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluorouracil		I-IUPAC
(		O
3		O
-		O
Thf		O
-		O
FU		O
,		O
5		O
)		O
was		O
formed		O
in		O
these		O
reactions		O
.		O
5		B-IUPAC
-		I-IUPAC
Deaza		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
propargylfolic		I-IUPAC
acid		I-IUPAC
(		O
4		O
)		O
,		O
an		O
analogue		O
of		O
the		O
thymidylate		O
synthase		O
(		O
TS		O
)		O
inhibitor		O
10		B-IUPAC
-		I-IUPAC
propargyl		I-IUPAC
-		I-IUPAC
5,8		I-IUPAC
-		I-IUPAC
dideazafolic		I-IUPAC
acid		I-IUPAC
(		O
PDDF		O
,		O
1		O
)		O
,		O
was		O
prepared		O
via		O
alkylation		O
of		O
diethyl		B-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
propargylamino		I-IUPAC
)		I-IUPAC
benzoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
(		O
7		O
)		O
by		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidinone		I-IUPAC
(		O
15		O
)		O
.		O
The		O
enantiomer		O
of		O
11a		O
,		O
i.e.		O
,		O
ent		O
-		O
11a		O
,		O
with		O
the		O
(		B-IUPAC
1S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
cyclopropane		I-IUPAC
structure		B-MODIFIER
turned		O
out		O
to		O
be		O
a		O
highly		O
potent		O
and		O
selective		O
H3		O
receptor		O
antagonist		O
with		O
a		O
Ki		O
of		O
3.6		O
nM		O
.		O
Methylation		O
of		O
4		O
with		O
CH2N2		O
and		O
subsequent		O
removal		O
of		O
the		O
benzyl		B-IUPAC
group		B-MODIFIER
by		O
catalytic		O
hydrogenation		O
provided		O
1		B-IUPAC
-		I-IUPAC
methylpyrazofurin		I-IUPAC
(		O
8		O
)		O
.		O
Insight		O
into		O
structure		O
-		O
activity		O
relationships		O
(		O
SAR		O
)		O
for		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamides		I-IUPAC
has		O
been		O
enhanced		O
by		O
studying		O
the		O
complex		O
formed		O
between		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
44		O
,		O
K		O
(		O
i		O
)		O
=		O
6		O
nM		O
)		O
and		O
the		O
catalytic		O
domain		O
of		O
chicken		O
PARP		O
.		O
In		O
a		O
sequence		O
of		O
reactions		O
,		O
methyl		O
mesopyropheophorbide		O
a		O
,		O
mesochlorin		B-IUPAC
e		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
trimethyl		I-IUPAC
ester		I-IUPAC
,		O
mesochlorin		B-IUPAC
p		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
trimethyl		I-IUPAC
ester		I-IUPAC
,		O
mesopurpurin		B-IUPAC
-		I-IUPAC
18		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
hexylimide		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
,		O
and		O
mesopurpurin		B-IUPAC
-		I-IUPAC
18		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
benzylimide		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
were		O
synthesized		O
from		O
chlorophyll		O
-		O
a		O
.		O
The		O
N3		O
-		O
substituted		O
derivatives		O
were		O
heated		O
with		O
a		O
mixture		O
of		O
3		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylaniline		I-IUPAC
and		O
its		O
hydrochloride		O
to		O
effect		O
displacement		O
of		O
the		O
6		O
-		O
amino		O
group		O
and		O
simultaneous		O
demethylation		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
group		B-MODIFIER
to		O
yield		O
target		O
compounds		O
in		O
good		O
yields		O
.		O
Thus		O
,		O
unlike		O
2,4		B-IUPAC
-		I-IUPAC
oxazolidinediones		I-IUPAC
,		O
N3		O
-		O
alkylation		O
of		O
hydantoins		O
dramatically		O
decreases		O
sodium		O
channel		O
-		O
binding		O
activity		O
.		O
Inhibitory		O
activity		O
of		O
cytosine		O
derivative		O
9c		O
is		O
reversed		O
with		O
uridine		O
and		O
2'		B-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
but		O
not		O
with		O
the		O
corresponding		O
cytosine		O
nucleosides		O
.		O
The		O
synthesis		O
and		O
sigma		O
1		O
and		O
sigma		O
2		O
binding		O
properties		O
of		O
several		O
(		B-PARTIUPAC
+		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
benzyl		I-PARTIUPAC
-		I-PARTIUPAC
and		O
2		B-IUPAC
-		I-IUPAC
dimethylallyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
substituted		I-IUPAC
-		I-IUPAC
5,9		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
benzomorphans		I-IUPAC
(		O
3		O
and		O
4		O
)		O
are		O
presented		O
.		O
High		O
DAT		O
affinity		O
and		O
selectivity		O
,		O
increased		O
locomotor		O
activity		O
with		O
slow		O
onset		O
and		O
long		O
duration		O
of		O
action		O
,		O
and		O
generalization		O
to		O
cocaine		O
shown		O
by		O
the		O
3beta		B-PARTIUPAC
-		I-PARTIUPAC
(		O
substituted		B-MODIFIER
phenyl		B-PARTIUPAC
)		O
-		I-PARTIUPAC
2beta		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
isoxazol		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
tropanes		I-IUPAC
are		O
properties		O
thought		O
necessary		O
for		O
a		O
pharmacotherapy		O
for		O
treating		O
cocaine		O
abuse		O
.		O
Preparation		O
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
alkyloxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
(		O
2-4		O
)		O
derivatives		B-MODIFIER
was		O
carried		O
out		O
based		O
on		O
alkylation		O
of		O
HEPT		O
with		O
primary		O
alkyl		O
halides		O
.		O
All		O
three		O
compounds		O
retained		O
antibacterial		O
activity		O
against		O
several		O
organisms		O
normally		O
susceptible		O
to		O
(		B-IUPAC
9R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
deoxo		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
erythromycin		I-IUPAC
A		I-IUPAC
.		O
This		O
process		O
is		O
characterized		O
by		O
a		O
transformation		O
of		O
the		O
conformation		O
of		O
lowest		O
potential		O
energy		O
to		O
one		O
with		O
an		O
energy		O
content		O
above		O
the		O
minimum		O
.		O
Compound		O
7		O
also		O
was		O
the		O
only		O
compound		O
which		O
demonstrated		O
significant		O
in		O
vivo		O
antifilarial		O
activity		O
against		O
the		O
adult		O
worms		O
of		O
Acanthocheilonema		O
viteae		O
in		O
experimentally		O
infected		O
jirds		O
.		O
Unlike		O
the		O
hydroxylated		O
DENSPM		O
compounds		O
,		O
both		O
cyclopropyl		O
norspermines		O
substantially		O
upregulated		O
spermidine		O
/		O
spermine		O
N		O
(		O
1		O
)		O
-		O
acetyltransferase		O
.		O
The		O
potency		O
of		O
iodoproxyfan		O
is		O
more		O
than		O
300		O
times		O
lower		O
at		O
H1		O
,		O
H2		O
,		O
alpha1		O
,		O
alpha2		O
,		O
beta1		O
,		O
5		O
-		O
HT2A		O
,		O
5		O
-		O
HT3		O
,		O
and		O
M3		O
receptors		O
than		O
at		O
histamine		O
H3		O
receptors		O
.		O
Debromination		O
of		O
3a		O
-		O
k		O
,		O
via		O
catalytic		O
hydrogenation		O
,		O
gave		O
the		O
corresponding		O
7		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
aminopyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
analogs		B-MODIFIER
4a		O
-		O
j		O
,		O
l		O
.		O
Among		O
the		O
compounds		O
synthesized		O
,		O
N		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
3,5		I-PARTIUPAC
-		I-PARTIUPAC
bis		I-PARTIUPAC
(		I-PARTIUPAC
trifluoromethyl		I-PARTIUPAC
)		I-PARTIUPAC
benzyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
7,8		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
,		I-PARTIUPAC
7		I-PARTIUPAC
-		I-PARTIUPAC
dimethyl		I-PARTIUPAC
-		I-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
oxo		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
substituted		B-MODIFIER
phenyl		B-IUPAC
)		B-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
pyrido		I-PARTIUPAC
[		I-PARTIUPAC
3,4		I-PARTIUPAC
-		I-PARTIUPAC
b		I-PARTIUPAC
]		I-PARTIUPAC
pyridinecarboxamides		I-PARTIUPAC
(		O
30a		O
,		O
f		O
,		O
g		O
)		O
showed		O
excellent		O
antagonist		O
activities		O
with		O
IC50		O
values		O
(		O
in		O
vitro		O
inhibition		O
of		O
[		O
125I		O
]		O
-		O
BH		O
-		O
SP		O
binding		O
in		O
human		O
IM		O
-		O
9		O
cells		O
)		O
of		O
0.21-0.34		O
nM		O
and		O
ED50		O
values		O
(		O
in		O
vivo		O
inhibition		O
of		O
capsaicin		O
-		O
induced		O
plasma		O
extravasation		O
in		O
guinea		O
-		O
pig		O
trachea		O
,		O
iv		O
)		O
of		O
0.017-0.030		O
mg		O
/		O
kg		O
.		O
The		O
inhibition		O
of		O
the		O
growth		O
of		O
leukemia		O
CCRF		O
-		O
CEM		O
cells		O
by		O
both		O
compounds		O
parallels		O
their		O
inhibition		O
of		O
CCRF		O
-		O
CEM		O
DHFR		O
.		O
On		O
the		O
other		O
hand		O
,		O
the		O
enantiomers		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
14b		O
,		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
15b		O
displayed		O
high		O
affinity		O
and		O
selectivity		O
for		O
the		O
D1		O
receptor		O
.		O
Am.		O
Chem.		O
Soc		O
.		O
[		O
18F		O
]		O
4c		O
was		O
superior		O
to		O
[		O
18F		O
]		O
4b		O
since		O
its		O
specific		O
binding		O
was		O
more		O
readily		O
blocked		O
by		O
4a		O
.		O
These		O
nucleosides		O
were		O
evaluated		O
for		O
in		O
vitro		O
cytotoxicity		O
to		O
human		O
prostate		O
cancer		O
(		O
HTB		O
-		O
81		O
)		O
and		O
mouse		O
melanoma		O
(		O
B16		O
)		O
cells		O
as		O
well		O
as		O
normal		O
human		O
fibroblasts		O
(		O
NHF		O
)		O
.		O
Alkylation		O
of		O
cytosine		O
with		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butene		I-IUPAC
gave		O
chloro		O
derivative		O
2f		O
,		O
which		O
was		O
hydrolyzed		O
to		O
alcohol		O
2h		O
.		O
One		O
of		O
the		O
most		O
potent		O
DNA		O
-		O
PK		O
inhibitors		O
identified		O
,		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
morpholin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
pyran		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
16		O
;		O
DNA		O
-		O
PK		O
;		O
IC50		O
=		O
220		O
nM		O
)		O
effectively		O
sensitized		O
HeLa		O
cells		O
to		O
the		O
topoisomerase		O
II		O
inhibitor		O
etoposide		O
in		O
vitro		O
.		O
The		O
results		O
of		O
the		O
enzymatic		O
test		O
indicate		O
that		O
the		O
nitrogen		O
in		O
the		O
3		O
-		O
position		O
,		O
and		O
secondly		O
,		O
the		O
nitrogen		O
in		O
the		O
5		O
-		O
position		O
are		O
very		O
important		O
for		O
the		O
interaction		O
of		O
the		O
azole		O
ring		O
with		O
the		O
inhibitory		O
site		O
on		O
the		O
enzyme		O
.		O
Amidification		O
was		O
successfully		O
carried		O
out		O
by		O
condensation		O
of		O
the		O
corresponding		O
acids		O
or		O
their		O
N		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
(		I-IUPAC
methyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
with		O
4		B-IUPAC
-		I-IUPAC
aminopyridine		I-IUPAC
promoted		O
by		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylpyridinium		I-IUPAC
iodide		I-IUPAC
.		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Phenylethynyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
dihydropyridine		I-IUPAC
derivatives		B-MODIFIER
are		O
selective		O
antagonists		O
at		O
human		O
A3		O
adenosine		O
receptors		O
,		O
with		O
Ki		O
values		O
in		O
a		O
radioligand		O
binding		O
assay		O
vs		O
[		O
125I		O
]		O
AB		O
-		O
MECA		O
(		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
iodobenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcarbamoyl		I-IUPAC
)		I-IUPAC
adenosine		I-IUPAC
)		O
in		O
the		O
submicromolar		O
range		O
.		O
We		O
have		O
now		O
combined		O
the		O
ring		O
-		O
constrained		O
(		O
N		O
)		O
-		O
methanocarba		O
modification		O
of		O
adenine		O
nucleotides		O
with		O
other		O
functionalities		O
known		O
to		O
enhance		O
potency		O
at		O
P2		O
receptors		O
.		O
The		O
key		O
intermediate		O
8		O
was		O
synthesized		O
starting		O
from		O
L		O
-		O
gulose		O
via		O
1,6		B-IUPAC
-		I-IUPAC
thioanhydro		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
gulopyranose		I-IUPAC
.		O
In		O
general		O
,		O
the		O
vinyl		O
and		O
ethylene		O
bridges		O
yielded		O
the		O
most		O
potent		O
analogs		O
while		O
the		O
propylene		O
-		O
bridged		O
analogs		O
were		O
among		O
the		O
least		O
potent		O
compounds		O
.		O
Rearrangement		O
of		O
the		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
picoline		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxides		I-IUPAC
with		O
Ac2O		O
yielded		O
respective		O
methyl		O
acetates		O
,		O
which		O
upon		O
acid		O
hydrolysis		O
,		O
MnO2		O
oxidation		O
,		O
and		O
reaction		O
with		O
thiosemicarbazide		O
resulted		O
in		O
the		O
desired		O
compounds		O
.		O
However		O
,		O
the		O
most		O
selective		O
sigma		O
2		O
versus		O
sigma		O
1		O
ligand		O
was		O
the		O
tropane		O
derivative		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
azabicyclo		I-IUPAC
[		I-IUPAC
3.2.1		I-IUPAC
]		I-IUPAC
oct		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indole		I-IUPAC
,		O
15a		O
.		O
New		O
compounds		O
of		O
the		O
nitroimidazole		O
series		O
have		O
been		O
synthesized		O
as		O
radiosensitizers		O
which		O
selectively		O
sensitize		O
hypoxic		O
cells		O
to		O
the		O
lethal		O
effect		O
of		O
radiation		O
.		O
Compound		O
3		O
was		O
obtained		O
via		O
a		O
Wittig		O
reaction		O
of		O
the		O
tributylphosphonium		O
salt		O
of		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
chloromethyl		I-IUPAC
)		I-IUPAC
furo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
5		O
)		O
and		O
methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
formylbenzoate		I-IUPAC
(		O
6		O
)		O
followed		O
by		O
reduction		O
and		O
coupling		O
with		O
the		O
diethyl		O
ester		O
of		O
L		B-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
.		O
Each		O
isomer		O
afforded		O
high		O
yields		O
of		O
7		B-IUPAC
-		I-IUPAC
chloromethyl		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
methylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
5		O
)		O
on		O
treatment		O
with		O
hydrogen		O
chloride		O
in		O
ethyl		O
acetate		O
.		O
A		O
series		O
of		O
polyamines		O
based		O
on		O
the		O
high		O
affinity		O
sigma		O
receptor		O
ligand		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
ethylamine		I-IUPAC
(		O
3		O
)		O
were		O
developed		O
and		O
evaluated		O
for		O
their		O
binding		O
characteristics		O
at		O
sigma		O
-		O
1		O
and		O
sigma		O
-		O
2		O
receptor		O
subtypes		O
.		O
It		O
is		O
highly		O
likely		O
that		O
nitrogen		O
lone		O
pair		O
orientations		O
and		O
steric		O
factors		O
on		O
the		O
aliphatic		O
portions		O
of		O
these		O
ligands		O
play		O
a		O
major		O
role		O
in		O
the		O
sigma		O
receptor		O
binding		O
of		O
this		O
pharmacophore		O
.		O
Whereas		O
the		O
classical		O
GABA		O
uptake		O
inhibitor		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nipecotic		I-IUPAC
acid		I-IUPAC
(		O
2		O
)		O
,		O
nonselectively		O
inhibits		O
neuronal		O
(		O
IC		O
(		O
50		O
)		O
=		O
12		O
microM		O
)		O
and		O
glial		O
(		O
IC		O
(		O
50		O
)		O
=		O
16		O
microM		O
)		O
GABA		O
uptake		O
and		O
4,5,6,7		B-IUPAC
-		I-IUPAC
tetrahydroisoxazolo		I-IUPAC
\C2		I-IUPAC
\BF		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
cpyridin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
1		O
,		O
THPO		O
)		O
shows		O
some		O
selectivity		O
for		O
glial		O
(		O
IC		O
(		O
50		O
)		O
=		O
268		O
microM		O
)		O
versus		O
neuronal		O
(		O
IC		O
(		O
50		O
)		O
=		O
530		O
microM		O
)		O
GABA		O
uptake		O
,		O
exo		O
-		O
THPO		O
(		O
8		O
)		O
was		O
shown		O
to		O
be		O
more		O
potent		O
as		O
an		O
inhibitor		O
of		O
glial		O
(		O
IC		O
(		O
50		O
)		O
=		O
200		O
microM		O
)		O
rather		O
than		O
neuronal		O
(		O
IC		O
(		O
50		O
)		O
=		O
900		O
microM		O
)		O
GABA		O
uptake		O
.		O
Carbamoylation		O
of		O
the		O
N		O
-		O
terminus		O
of		O
most		O
of		O
these		O
analogues		O
resulted		O
in		O
slightly		O
improved		O
affinity		O
,		O
selectivity		O
,		O
or		O
both		O
.		O
Synthesis		O
of		O
the		O
bay		O
region		O
anti		O
-		O
diol		O
epoxide		O
derivative		O
of		O
cholanthrene		O
,		O
its		O
putative		O
ultimate		O
carcinogenic		O
metabolite		O
,		O
is		O
also		O
described		O
.		O
In		O
the		O
cyclic		O
series		O
,		O
particularly		O
among		O
the		O
benzamides		O
of		O
1		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
aminopyrrolidine		I-IUPAC
,		O
most		O
of		O
the		O
compounds		O
tested		O
were		O
more		O
active		O
than		O
the		O
corresponding		O
linear		O
benzamides		O
.		O
A		O
release		O
study		O
,		O
employing		O
calcein		O
encapsulated		O
in		O
non		O
-		O
hydrolyzable		O
1,2		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
octadecyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphocholine		I-IUPAC
(		O
D		O
-		O
O		O
-		O
SPC		O
)		O
liposomes		O
,		O
showed		O
that		O
proAELs		O
,		O
activated		O
by		O
sPLA		O
(		O
2		O
)		O
,		O
perturb		O
membranes		O
because		O
of		O
the		O
detergent		O
-		O
like		O
properties		O
of		O
the		O
released		O
hydrolysis		O
products		O
.		O
The		O
chlorine		O
-		O
substituted		O
derivatives		O
3f		O
-		O
i		O
exhibited		O
potent		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptor		O
-		O
mediated		O
relaxation		O
of		O
ferret		O
detrusor		O
(		O
EC		O
(		O
50		O
)		O
=		O
0.93		O
,		O
11		O
,		O
14		O
,		O
and		O
160		O
nM		O
)		O
and		O
higher		O
potency		O
at		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptors		O
than		O
at		O
beta		O
(		O
1		O
)		O
or		O
beta		O
(		O
2		O
)		O
.		O
These		O
compounds		O
are		O
the		O
most		O
potent		O
inhibitors		O
of		O
the		O
kynurenine		O
-		O
3		O
-		O
hydroxylase		O
enzyme		O
so		O
far		O
disclosed		O
.		O
The		O
most		O
potent		O
compounds		O
were		O
oxidized		O
to		O
the		O
paramagnetic		O
nitroxides		O
and		O
the		O
latter		O
were		O
reduced		O
to		O
the		O
N		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
derivatives		B-MODIFIER
;		O
these		O
products		O
had		O
no		O
or		O
only		O
decreased		O
antiarrhythmic		O
effect		O
.		O
A		O
significant		O
finding		O
was		O
that		O
monocyclic		O
5		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
oxazolidinediones		I-IUPAC
provided		O
relatively		O
potent		O
,		O
nontoxic		O
,		O
broad		O
-		O
spectrum		O
anticonvulsants		O
.		O
After		O
our		O
discovery		O
that		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Phe		O
-		O
DNal		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
ODN		O
-		O
8		O
)		O
had		O
high		O
affinity		O
and		O
marginal		O
selectivity		O
for		O
human		O
sst		O
(		O
3		O
)		O
(		O
part		O
2		O
of		O
this		O
series		O
:		O
Erchegyi		O
et		O
al.		O
J		O
.		O
All		O
compounds		O
were		O
tested		O
for		O
their		O
H3		O
receptor		O
antagonist		O
activity		O
in		O
a		O
[		O
3H		O
]		O
-		O
histamine		O
-		O
release		O
assay		O
with		O
synaptosomes		O
from		O
rat		O
cerebral		O
cortex		O
.		O
Med.		O
Chem.		O
,		O
preceding		O
paper		O
in		O
this		O
issue		O
)		O
(		O
11		O
)		O
and		O
that		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Phe		O
-		O
DTrp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
ODT		O
-		O
8		O
,		O
3		O
)		O
had		O
high		O
affinity		O
and		O
marginal		O
selectivity		O
for		O
human		O
sst		O
(		O
4		O
)		O
,		O
that		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Tyr		O
-		O
D		O
-		O
threo		O
-		O
beta		O
-		O
Me2Nal		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
had		O
high		O
affinity		O
for		O
all		O
sst		O
's		O
except		O
for		O
sst		O
(		O
1		O
)		O
,		O
and		O
that		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Tyr		O
-		O
L		O
-		O
threo		O
-		O
beta		O
-		O
Me2Nal		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
had		O
high		O
affinity		O
for		O
sst		O
(		O
4		O
)		O
(		O
IC		O
(		O
50		O
)		O
=		O
2.1		O
nM		O
)		O
,		O
with		O
more		O
than		O
50		O
-		O
fold		O
selectivity		O
toward		O
the		O
other		O
receptors		O
(		O
parts		O
1		O
and		O
2		O
of		O
this		O
series		O
:		O
Rivier		O
et		O
al.		O
and		O
Erchegyi		O
et		O
al.		O
J		O
.		O
mol		O
-		O
1		O
)		O
between		O
the		O
most		O
and		O
the		O
least		O
favorable		O
conformations		O
.		O
In		O
the		O
current		O
study		O
,		O
a		O
similar		O
approach		O
was		O
applied		O
to		O
the		O
3		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxymethyloxyphenylalanyl		I-IUPAC
-		O
containing		O
peptide		O
,		O
which		O
led		O
to		O
the		O
preparation		O
of		O
monomeric		O
5		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxymethyloxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
(		O
K		O
(		O
i		O
)		O
=		O
900		O
microM		O
)		O
.		O
cruzi		O
,		O
with		O
either		O
trypanothione		O
disulfide		O
or		O
N		B-IUPAC
-		I-IUPAC
benzyloxycarbonyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
cysteinylglycyl		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dimethylaminopropylamide		I-IUPAC
disulfide		I-IUPAC
as		O
substrate		O
.		O
The		O
m		O
-		O
fluorophenylalanine		O
analog		O
demonstrated		O
the		O
best		O
delta		O
binding		O
of		O
the		O
group		O
,		O
with		O
a		O
Ki		O
of		O
4.79		O
nM		O
.		O
Both		O
the		O
t		O
-		O
Hpp1		O
and		O
c		O
-		O
Hpp1		O
analogues		O
displayed		O
delta		O
receptor		O
binding		O
affinity		O
similar		O
to		O
the		O
parent		O
Tyr1		O
-		O
containing		O
peptide		O
,		O
while		O
the		O
D		O
-		O
Hat1		O
,		O
L		O
-		O
Hat1		O
,		O
and		O
L		O
-		O
Hai1		O
analogues		O
exhibited		O
somewhat		O
lower		O
affinity		O
.		O
In		O
fact		O
,		O
the		O
pyrazole		O
and		O
the		O
2		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
1,2,3		B-IUPAC
-		I-IUPAC
triazole		I-IUPAC
derivatives		B-MODIFIER
(		O
10		O
and		O
15		O
,		O
respectively		O
)		O
are		O
nearly		O
inactive		O
,		O
whereas		O
the		O
erythro		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazole		I-IUPAC
(		O
18e		O
)		O
was		O
the		O
most		O
potent		O
ADA		O
inhibitor		O
in		O
the		O
series		O
with		O
Ki		O
=		O
0.3		O
microM		O
.		O
THMNDs		O
were		O
prepared		O
via		O
a		O
Diels		O
-		O
Alder		O
reaction		O
with		O
2		B-IUPAC
-		I-IUPAC
methoxybenzoquinone		I-IUPAC
(		O
5		O
)		O
or		O
2		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxybenzoquinone		I-IUPAC
(		O
14		O
)		O
and		O
substituted		B-MODIFIER
1,3		B-IUPAC
-		I-IUPAC
butadienes		I-IUPAC
.		O
The		O
present		O
work		O
reports		O
the		O
synthesis		O
of		O
enantiomeric		O
pairs		O
of		O
the		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indene		I-IUPAC
[		O
(		O
+		O
)		O
-		O
14a		O
,		O
(		O
-		O
)		O
-		O
14a		O
]		O
and		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
H		I-IUPAC
-		I-IUPAC
indene		I-IUPAC
[		O
(		O
+		O
)		O
-		O
14b		O
,		O
(		O
-		O
)		O
-		O
14b		O
]		O
and		O
their		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
[		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
15a		O
,		O
b		O
]		O
,		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
[		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
16a		O
,		O
b		O
]		O
,		O
and		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
[		O
(		O
+		O
)		O
and		O
(		O
-		O
)		O
-		O
17a		O
,		O
b		O
]		O
derivatives		B-MODIFIER
obtained		O
by		O
a		O
combination		O
of		O
stereospecific		O
reactions		O
and		O
optical		O
resolution		O
.		O
Methylation		O
of		O
the		O
hydroxyl		B-IUPAC
group		B-MODIFIER
of		O
HEPT		O
did		O
not		O
affect		O
the		O
anti		O
-		O
HIV		O
-		O
1		O
activity		O
of		O
HEPT		O
.		O
As		O
a		O
continuation		O
of		O
our		O
earlier		O
study		O
(		O
J		O
.		O
The		O
metabolic		O
fate		O
of		O
tolazamide		O
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hexahydroazepin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
tolylsulfonylurea		I-IUPAC
(		O
1		O
)		O
,		O
was		O
studied		O
in		O
man		O
and		O
in		O
the		O
rat		O
using		O
tritium		O
-		O
labeled		O
1		O
.		O
Condensation		O
of		O
compounds		O
32		O
and		O
39		O
with		O
thiosemicarbazide		O
afforded		O
the		O
respective		O
4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-PARTIUPAC
-		I-PARTIUPAC
acetoxy		I-PARTIUPAC
(		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
and		O
4		B-PARTIUPAC
-		I-PARTIUPAC
methyl		I-PARTIUPAC
)		I-PARTIUPAC
thiosemicarbazones		I-PARTIUPAC
33		O
and		O
40		O
,		O
which		O
were		O
then		O
converted		O
to		O
their		O
respective		O
4		O
-		O
and		O
5		O
-		O
hydroxy		O
derivatives		O
34		O
and		O
41		O
by		O
acid		O
hydrolysis		O
.		O
Its		O
efficiency		O
in		O
inhibition		O
of		O
microvascular		O
permeability		O
was		O
assessed		O
in		O
two		O
rhinitis		O
models		O
;		O
ovalbumin		O
and		O
capsaicin		O
-		O
induced		O
rhinorrhea		O
could		O
be		O
prevented		O
after		O
topical		O
application		O
of		O
submicromolar		O
concentrations		O
of		O
45		O
(		O
IC50		O
=		O
0.25		O
and		O
0.30		O
microM		O
)		O
;		O
and		O
it		O
also		O
exerted		O
significant		O
inhibitory		O
effect		O
in		O
the		O
first		O
test		O
after		O
iv		O
and		O
oral		O
administration		O
,		O
with		O
ID50		O
=		O
0.005		O
and		O
0.46		O
mg		O
/		O
kg		O
.		O
The		O
three		O
compounds		O
AMPA		O
,		O
ATPA		O
,		O
and		O
ABPA		O
are		O
agonists		O
at		O
the		O
class		O
of		O
receptors		O
assumed		O
to		O
represent		O
a		O
subtype		O
of		O
physiological		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
(		O
Glu		O
)		O
receptors		O
.		O
Several		O
of		O
these		O
compounds		O
,		O
such		O
as		O
6b		O
,		O
e		O
,		O
were		O
particularly		O
interesting		O
inhibitors		O
of		O
HCMV		O
with		O
IC		O
(		O
50		O
)		O
's		O
ranging		O
from		O
0.1		O
to		O
1.3		O
muM		O
.		O
The		O
structural		O
features		O
of		O
5		O
may		O
well		O
reflect		O
optimal		O
agonist		O
interaction		O
at		O
the		O
NMDA		O
receptor		O
site		O
.		O
They		O
inhibited		O
the		O
growth		O
of		O
Gram		O
-		O
positive		O
bacteria		O
and		O
pathogenic		O
fungi		O
at		O
MIC		O
range		O
3		O
x		O
10		O
(		O
-		O
2		O
)		O
to		O
2.5		O
x		O
10		O
(		O
-		O
1		O
)		O
mumol		O
/		O
mL		O
,		O
displayed		O
cytotoxicity		O
against		O
KB		O
cells		O
ID50		O
in		O
the		O
range		O
2		O
x		O
10		O
(		O
-		O
3		O
)		O
to		O
9		O
x		O
10		O
(		O
-		O
3		O
)		O
mumol		O
/		O
mL		O
,		O
and		O
stimulated		O
the		O
formation		O
of		O
calf		O
thymus		O
topoisomerase		O
II		O
mediated		O
DNA		O
cleavage		O
at		O
concentration		O
between		O
0.4		O
and		O
10		O
microM		O
.		O
Nineteen		O
previously		O
undescribed		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,6,7		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
tetrahydroquinazolines		I-IUPAC
(		O
5a		O
-		O
m		O
,		O
10-12		O
)		O
were		O
synthesized		O
as		O
part		O
of		O
a		O
larger		O
effort		O
to		O
assess		O
the		O
therapeutic		O
potential		O
of		O
lipophilic		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
inhibitors		O
against		O
opportunistic		O
infections		O
of		O
AIDS		O
.		O
Following		O
alpha		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
and		O
alpha		B-IUPAC
-		I-IUPAC
carboxyl		I-IUPAC
deprotections		B-MODIFIER
of		O
11		O
and		O
12		O
,		O
EEDQ		O
[		O
2		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
dihydroquinoline		I-IUPAC
]		O
mediated		O
peptide		O
coupling		O
and		O
final		O
deprotection		O
provided		O
amino		O
acid		O
1		O
and		O
six		O
albomycin		O
-		O
like		O
peptides		O
(		O
20		O
,		O
23		O
,		O
25		O
,		O
28		O
,		O
35		O
,		O
and		O
36		O
)		O
.		O
It		O
is		O
known		O
that		O
the		O
HCV		O
-		O
E2		O
envelope		O
glycoprotein		O
binds		O
to		O
the		O
CD81		O
protein		O
.		O
With		O
a		O
benzoic		O
acid		O
group		O
as		O
part		O
of		O
the		O
structure		O
attached		O
to		O
the		O
thiochroman		O
unit		O
,		O
the		O
ODC		O
activity		O
was		O
enhanced		O
as		O
shown		O
in		O
10		O
and		O
11		O
.		O
CD81		O
is		O
a		O
member		O
of		O
the		O
tetraspanin		O
family		O
of		O
membrane		O
proteins		O
found		O
in		O
all		O
cell		O
lineages		O
in		O
the		O
liver		O
.		O
The		O
conformational		O
properties		O
of		O
the		O
parent		O
tetrapeptide		O
and		O
the		O
residue		O
1		O
-		O
modified		O
analogues		O
were		O
studied		O
by		O
molecular		O
mechanics		O
computations		O
.		O
As		O
part		O
of		O
an		O
effort		O
to		O
develop		O
a		O
new		O
class		O
of		O
subtype		O
selective		O
nicotine		O
agonists		O
,		O
we		O
have		O
synthesized		O
and		O
tested		O
a		O
group		O
of		O
12		O
hydroxylated		O
2		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
piperidyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyrrolidyl		I-IUPAC
)		I-IUPAC
chromans		I-IUPAC
.		O
Compound		O
48		O
sensitized		O
the		O
HeLa		O
human		O
tumor		O
cell		O
line		O
to		O
the		O
cytotoxic		O
effects		O
of		O
ionizing		O
radiation		O
in		O
vitro		O
,		O
a		O
dose		O
modification		O
factor		O
of		O
2.3		O
at		O
10%		O
survival		O
being		O
observed		O
with		O
an		O
inhibitor		O
concentration		O
of		O
5		O
microM		O
.		O
Based		O
on		O
these		O
studies		O
,		O
one		O
compound		O
,		O
5		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorobenzyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
65		O
)		O
,		O
was		O
selected		O
for		O
preclinical		O
toxicity		O
evaluation		O
.		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
[		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
Chloroethyl		I-IUPAC
)		I-IUPAC
carbamyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
norapocodeine		I-IUPAC
(		O
1g		O
)		O
and		O
its		O
11		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
carbamyl		I-IUPAC
derivative		B-MODIFIER
(		O
1h		O
)		O
were		O
also		O
prepared		O
.		O
To		O
provide		O
a		O
direct		O
and		O
quantitative		O
assessment		O
of		O
the		O
contributions		O
of		O
several		O
conserved		O
residues		O
around		O
the		O
binding		O
site		O
to		O
PKC		O
-		O
ligand		O
binding		O
,		O
we		O
have		O
made		O
11		O
mutations		O
and		O
measured		O
the		O
binding		O
affinities		O
of		O
the		O
high		O
-		O
affinity		O
PKC		O
ligands		O
to		O
these		O
mutants		O
.		O
N		B-IUPAC
-		I-IUPAC
Methoxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methoxyamidino		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
nicotinamidine		I-IUPAC
(		O
6a		O
)		O
was		O
prepared		O
via		O
methylation		O
of		O
the		O
respective		O
diamidoxime		O
5a		O
with		O
dimethylsulfate		O
.		O
Each		O
target		O
compound		O
was		O
obtained		O
in		O
five		O
steps		O
starting		O
from		O
cyclopent		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
enone		I-IUPAC
.		O
;		O
Hurley		O
,		O
L		O
.		O
The		O
4		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluoromuscarines		I-IUPAC
display		O
a		O
similar		O
trend		O
of		O
potency		O
as		O
the		O
corresponding		O
muscarines		O
and		O
compound		O
1a		O
shows		O
differences		O
in		O
the		O
affinity		O
constants		O
among		O
the		O
studied		O
tissues		O
.		O
The		O
unselective		O
excitatory		O
amino		O
acid		O
activity		O
of		O
21		O
is		O
comparable		O
with		O
6,7		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
quinoxaline		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
and		O
6,7		B-IUPAC
-		I-IUPAC
dichloroquinoxalic		I-IUPAC
acid		I-IUPAC
and		O
this		O
suggests		O
similarities		O
in		O
their		O
modes		O
of		O
binding		O
to		O
excitatory		O
amino		O
acid		O
receptors		O
.		O
The		O
effectiveness		O
of		O
inhibition		O
was		O
reduced		O
with		O
an		O
increase		O
in		O
size		O
of		O
the		O
halogen		O
atom		O
.		O
The		O
2		O
-		O
substituted		O
histamine		O
analogues		O
were		O
partial		O
H1		O
receptor		O
agonists		O
on		O
the		O
endothelium		O
-		O
denuded		O
isolated		O
guinea		O
pig		O
aorta		O
with		O
pEC50		O
values		O
generally		O
smaller		O
than		O
observed		O
on		O
the		O
guinea		O
pig		O
ileum		O
,		O
but		O
the		O
rank		O
order		O
of		O
potency		O
was		O
found		O
to		O
be		O
similar		O
.		O
Affinities		O
ranged		O
from		O
582		O
nM		O
[		O
(		O
+		O
/		O
-		O
)		O
-		O
9		O
]		O
to		O
29,000		O
nM		O
[		O
(		O
+		O
)		O
-		O
8		O
]		O
at		O
PCP		O
binding		O
sites		O
and		O
from		O
1130		O
nM		O
[		O
(		O
-		O
)		O
-		O
8		O
]		O
to		O
16,300		O
nM		O
(		O
7		O
)		O
at		O
sigma		O
sites		O
.		O
As		O
far		O
as		O
the		O
potency		O
at		O
the		O
A		O
(		O
2B		O
)		O
receptor		O
,		O
the		O
type		O
of		O
2		O
-		O
alkynyl		O
chain		O
and		O
the		O
presence		O
of		O
the		O
ethylcarboxamido		O
group		O
on		O
the		O
sugar		O
seem		O
to		O
be		O
very		O
important		O
;		O
in		O
fact		O
,		O
the		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylhydroxypropynyl		I-IUPAC
NECA		O
[		O
(		O
S		O
)		O
-		O
PHPNECA		O
,		O
1e		O
,		O
EC		O
(		O
50		O
)		O
(		O
A		O
(		O
2B		O
)		O
)		O
=		O
0.22		O
microM		O
]		O
proved		O
to		O
be		O
one		O
of		O
the		O
most		O
potent		O
A		O
(		O
2B		O
)		O
agonist		O
reported		O
so		O
far		O
.		O
The		O
compounds		O
also		O
were		O
less		O
active		O
against		O
human		O
cytomegalovirus		O
(		O
HCMV		O
)		O
and		O
herpes		O
simplex		O
virus		O
type		O
1		O
(		O
HSV		O
-		O
1		O
)		O
.		O
Alternatively		O
,		O
the		O
above		O
-		O
indicated		O
compounds		O
were		O
prepared		O
from		O
amines		O
and		O
17		B-IUPAC
-		I-IUPAC
keto		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
azasteroids		I-IUPAC
to		O
form		O
imines		O
,		O
which		O
were		O
then		O
reduced		O
with		O
NaBH4		O
.		O
Certain		O
novel		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalenes		I-IUPAC
(		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
aminotetralins		I-IUPAC
,		O
PATs		O
)		O
produced		O
stimulation		O
(		O
ca.		O
30%		O
above		O
basal		O
levels		O
)		O
of		O
tyrosine		O
hydroxylase		O
(		O
TH		O
)		O
activity		O
at		O
0.1		O
microM		O
concentrations		O
in		O
rodent		O
brain		O
tissue		O
.		O
A		O
library		O
of		O
compounds		O
were		O
prepared		O
by		O
reacting		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
(		I-IUPAC
2H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
(		O
5		O
)		O
with		O
commercially		O
available		O
carboxylic		O
acids		O
in		O
the		O
presence		O
of		O
potassium		O
carbonate		O
or		O
a		O
tertiary		O
amine		O
base		O
.		O
In		O
order		O
to		O
selectively		O
determine		O
affinities		O
for		O
the		O
high		O
-		O
affinity		O
agonist		O
binding		O
site		O
at		O
DA		O
D2		O
receptors		O
,		O
the		O
agonist		O
[		O
3H		O
]		O
quinpirole		O
was		O
used		O
.		O
In		O
this		O
case		O
,		O
highest		O
inhibitory		O
activity		O
was		O
obtained		O
by		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
decyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dimethylpropanamid		I-IUPAC
e		I-IUPAC
(		O
65		O
)		O
.		O
In		O
addition		O
,		O
aralkyl		B-IUPAC
,		O
alkyl		B-IUPAC
,		O
and		O
cycloalkyl		B-IUPAC
carboxylates		B-IUPAC
of		O
the		O
4		B-IUPAC
-		I-IUPAC
piperidinol		I-IUPAC
system		B-MODIFIER
and		O
3,4		B-IUPAC
-		I-IUPAC
dimethoxybenzoates		I-IUPAC
of		O
isomeric		O
piperidinols		O
(		O
24-26		O
)		O
were		O
synthesized		O
.		O
The		O
toxicity		O
of		O
2,6		B-IUPAC
-		I-IUPAC
dimethylacetaminophen		I-IUPAC
and		O
3,5		B-IUPAC
-		I-IUPAC
dimethylacetaminophen		I-IUPAC
was		O
examined		O
histologically		O
in		O
mice		O
and		O
rats		O
.		O
In		O
the		O
new		O
orientation		O
,		O
the		O
naphthyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxyl		I-IUPAC
group		B-MODIFIER
,		O
and		O
not		O
the		O
o		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
carboxymethyloxy		I-IUPAC
groups		B-MODIFIER
,		O
mimics		O
a		O
phosphoryl		O
group		O
.		O
By		O
contrast		O
,		O
compound		O
17		O
might		O
be		O
partial		O
agonist		O
at		O
the		O
purinergic		O
inhibitory		O
(		O
A1		O
)		O
receptor		O
.		O
administration		O
of		O
a		O
single		O
dose		O
of		O
1		O
mg		O
/		O
kg		O
and		O
also		O
provided		O
100%		O
inhibition		O
of		O
PAF		O
-		O
induced		O
aggregation		O
in		O
dog		O
whole		O
blood		O
6		O
h		O
after		O
i		O
.		O
A		O
number		O
of		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
:		I-IUPAC
N'		I-IUPAC
,		I-IUPAC
N'		I-IUPAC
:		I-IUPAC
N		I-IUPAC
"		I-IUPAC
,		I-IUPAC
N		I-IUPAC
"		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
ethanediylphosphoric		I-IUPAC
triamide		I-IUPAC
(		O
TEPA		O
)		O
and		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
:		I-IUPAC
N'		I-IUPAC
,		I-IUPAC
N'		I-IUPAC
:		I-IUPAC
N		I-IUPAC
"		I-IUPAC
,		I-IUPAC
N		I-IUPAC
"		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
ethanediylphosphorothioic		I-IUPAC
triamide		I-IUPAC
(		O
thio		O
-		O
TEPA		O
)		O
derivatives		O
containing		O
either		O
two		O
aziridine		B-IUPAC
moieties		B-MODIFIER
(		O
1a		O
)		O
or		O
two		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
functions		B-MODIFIER
(		O
1b		O
)		O
and		O
either		O
a		O
2,2,6,6		B-IUPAC
-		I-IUPAC
tetramethylpiperidine		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
oxy		I-IUPAC
-		I-IUPAC
2,2,6,6		I-IUPAC
-		I-IUPAC
tetramethylpiperidine		I-IUPAC
or		O
1		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2,2,6,6		I-IUPAC
-		I-IUPAC
tetramethylpiperidine		I-IUPAC
component		B-MODIFIER
were		O
synthesized		O
and		O
tested		O
against		O
lymphocytic		O
leukemia		O
P388		O
in		O
mice		O
.		O
A		O
broad		O
screening		O
of		O
phytochemicals		O
has		O
demonstrated		O
that		O
certain		O
flavone		O
and		O
flavonol		O
derivatives		O
have		O
a		O
relatively		O
high		O
affinity		O
at		O
A3		O
adenosine		O
receptors		O
,		O
with		O
Ki		O
values		O
of		O
&		O
gt		O
;		O
or		O
=		O
1		O
microM		O
(		O
Ji		O
et		O
al.		O
J		O
.		O
Compound		O
139		O
,		O
3,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
oxadiazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phthalazineacetic		I-IUPAC
acid		I-IUPAC
,		O
with		O
IC50		O
less		O
than		O
1.0		O
x		O
10		O
(		O
-		O
8		O
)		O
M		O
,		O
caused		O
a		O
69%		O
reduction		O
in		O
sorbitol		O
accumulation		O
in		O
rat		O
sciatic		O
nerve		O
at		O
an		O
oral		O
dose		O
of		O
25		O
mg		O
/		O
kg		O
.		O
Acta		O
1972		O
,		O
284		O
,		O
427-434		O
.		O
The		O
inactive		O
isomeric		O
indolones		O
38		O
,		O
39		O
,		O
and		O
41		O
were		O
derived		O
from		O
4		B-IUPAC
-		I-IUPAC
nitrobenzeneethanamine		I-IUPAC
and		O
from		O
indolone		B-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
.		O
High		O
-		O
affinity		O
compounds		O
with		O
high		O
selectivity		O
for		O
the		O
5		O
-		O
HT1A		O
receptor		O
were		O
found		O
among		O
structures		O
substituted		O
with		O
carboxylate		O
esters		O
,		O
amides		O
,		O
and		O
ketones		O
in		O
the		O
5		O
-		O
position		O
.		O
Saturation		O
of		O
the		O
double		O
bond		O
of		O
some		O
pyrroline		B-IUPAC
derivatives		B-MODIFIER
furnished		O
the		O
pyrrolidinecarboxamides		O
.		O
It		O
decreased		O
the		O
basal		O
[		O
35S		O
]		O
GTP		O
gamma		O
S		O
binding		O
and		O
potently		O
inhibited		O
the		O
DA		O
-		O
stimulated		O
[		O
35S		O
]		O
GTP		O
gamma		O
S		O
binding		O
.		O
Crystallization		O
of		O
the		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
mandelate		I-IUPAC
salt		I-IUPAC
afforded		O
(		O
1R		O
,		O
2R		O
,		O
5S		O
)		O
-		O
(		O
-		O
)		O
-		O
16		O
,		O
whereas		O
the		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
mandelate		I-IUPAC
salt		I-IUPAC
afforded		O
(		O
1S		O
,		O
2S		O
,		O
5R		O
)		O
-		O
(		O
+		O
)		O
-		O
16		O
;		O
the		O
absolute		O
configuration		O
was		O
determined		O
by		O
single		O
-		O
crystal		O
X		O
-		O
ray		O
analysis		O
of		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
16		I-IUPAC
.		I-IUPAC
For		O
example		O
,		O
N		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
-		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
methylguanidine		I-IUPAC
(		O
40		O
)		O
showed		O
high		O
affinity		O
for		O
the		O
NMDA		O
receptor		O
ion		O
channel		O
site		O
(		O
IC50		O
=		O
36		O
nM		O
vs		O
[		O
3H		O
]		O
-		O
3		O
)		O
and		O
low		O
affinity		O
for		O
sigma		O
receptors		O
(		O
IC50		O
=		O
2540		O
nM		O
vs		O
[		O
3H		O
]		O
-		O
5		O
)		O
.		O
2		B-PARTIUPAC
-		I-PARTIUPAC
Fluoro		I-PARTIUPAC
-		I-PARTIUPAC
,		O
5		B-PARTIUPAC
-		I-PARTIUPAC
fluoro		I-PARTIUPAC
-		I-PARTIUPAC
and		O
6		B-IUPAC
-		I-IUPAC
fluorodimethoxybenzaldehydes		I-IUPAC
were		O
prepared		O
by		O
photochemical		O
decomposition		O
of		O
the		O
corresponding		O
diazonium		O
fluoroborates		O
.		O
The		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
compounds		B-MODIFIER
5		O
and		O
6		O
were		O
as		O
potent		O
inhibitors		O
of		O
DHFR		O
from		O
L1210		O
cells		O
as		O
MTX		O
and		O
7		O
-		O
and		O
35		O
-		O
fold		O
,		O
respectively		O
,		O
more		O
inhibitory		O
than		O
MTX		O
toward		O
L1210		O
cell		O
growth		O
.		O
The		O
introduction		O
of		O
a		O
cycloaliphatic		O
five		O
-		O
or		O
six		O
-		O
membered		O
ring		O
fused		O
at		O
the		O
thiophene		O
was		O
favorable		O
for		O
CEase		O
inhibition		O
.		O
N		B-IUPAC
-		I-IUPAC
Bromosuccinimide		I-IUPAC
treatment		O
of		O
13		O
,		O
20		O
,		O
and		O
25		O
afforded		O
the		O
3		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
derivatives		B-MODIFIER
15		O
,		O
21		O
,		O
and		O
25		O
.		O
